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Abstract 
 
Around 10% of desmoid tumours (DT) in familial adenomatous polyposis 
(FAP) patients grow relentlessly, causing major morbidity and mortality.  
Radiological, clinical or cellular predictors of aggressive DT are yet to be 
identified. The work described in this dissertation aimed to identify such 
predictors by radiological studies, and to develop management guidelines 
and identify possible targets for therapy. 
  
Nine FAP patients with DT underwent 64 multi detector computed 
tomography (64-MDCT), 1.5 Telsa magnetic resonance imaging (1.5T MRI), 
Diffusion Tensor Imaging (DTI), Dynamic Contrast Enhanced MRI (DCE-
MRI) and Fluorine-18 Flurodeoxyglucose Positron Emission Tomography 
(18F-FDG PET CT). Direct comparision between 1.5T MRI and 64-MDCT 
found that MRI was at least equivalent to MDCT in the assessment of DT. DTI 
was feasible and detected an anisotropic diffusion, which was less directional 
than in muscle. Metabolic (FDG PET) and vascular imaging (DCE-MRI) of DT 
demonstrated a spectrum of findings and found that DT were generally 
hypovascular and poorly glucose avid. 
 
A review of nine FAP patients with intra-abdominal desmoid (IAD) and air-
fluid level (AFL) on cross sectional imaging found that either a direct 
communication or translocation of microorganism from bowel led to the 
development of AFL. Some of these patients could be treated successfully 
with antibiotics and/or a percutaneous drain; however, the majority 
ultimately required complex surgery.  
 
Full sequence APC mutation analysis performed in three primary DT cell 
lines detected ‘second hit’ somatic mutation in only one, confirming the 
establishment of a true DT cell line. A study of choline metabolism using 
choline kinase alpha (CHKA) as a marker for activation, however, failed to 
demonstrate up regulation of choline metabolism in desmoid tumour cells. 
Studies of the Wnt signalling pathways confirmed the activation of canonical 
Wnt signalling in DT. Interestingly Wnt11, a non-canonical Wnt, was also up 
regulated in DT. 
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Chapter 1 
 
 
 
 
Introduction 
 
 
 
1.1   Familial Adenomatous Polyposis 
 
 
 
Familial adenomatous polyposis (FAP) is an autosomal dominant colorectal 
cancer predisposition syndrome caused by inheritence of or a new mutation 
in the adenomatous polyposis coli (APC) tumour suppressor gene. 
Polpulation prevalence of FAP is between 1 in 7,500 and 1 in 13,000 and the 
disease penetrance nearly reaches 100 percent by the age of 40 years (Bisgaard 
et al, 1994).   
 
FAP predisposes to development of numerous adenomatous polyps in the 
colorectum, which inevitably progress to carcinoma if left untreated. 
However, other parts of gastrointestinal tract such as the stomach and 
duodenum are also involved in FAP. Gastric lesions seen in FAP are usually 
fundic gland polyps without malignant potential (Wu et al, 1998). 
Adenomatosis of duodenum, particularly involving the ampullary region is 
seen in nearly ninety percent of FAP patients, however, only ten percent of 
these progress to periampullary cancer (Clark et al, 2009).  
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1.1.1 The APC gene and APC Protein  
 
In 1982 Herrera et al first described an interstitial deletion of 5q chromosome 
in a mentally retarded patient with multiple developmental abnormalities 
and colorectal polyposis. Bodmer et al later localized the gene to chromosome 
5 near bands 5q21-5q22 in FAP patients (Bodmer et al, 1987). Two different 
groups working independently subsequently identified the mutation in the 
Adenomatous Polyposis Coli (APC) gene as the cause of FAP (Groden et al, 
1991; Kinzler et al, 1991).   
 
APC is a large gene and consists of 8535 bp spanning 21 exons (Fernhead et al, 
2001). Over 75 percent of the coding sequence of the APC gene is contributed 
by exon 15 which is the also the region in which the majority of germline and 
somatic mutations occur (Beroud et al, 1996).  
 
APC encodes a 2843 amino acid protein, which is broadly expressed 
throughout the human body. APC protein is implicated in wide variety of 
cellular processes including cell migration, cell adhesion, chromosome 
segregation, spindle assembly, apoptosis and neuronal differentiation 
(Hanson et al, 2005). Despite these many roles, the classic function of APC in 
neoplasia is inhibition of Wnt signalling pathway. Details of the Wnt 
signaling pathway are described in the section on desmoid tumour (1.2.3).   
 
APC primarily works as a negative regulator of neoplasia. A germline 
mutation in the APC gene predisposes patients with FAP to develop 
colorectal polyposis. A second hit somatic mutation in the other allele of APC 
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results in the intestinal tumourigenesis and desmoid development, a feature 
consitent with Knudson’s two-hit hypothesis (Miyoshi et al 1992; Miyaki et al, 
1994). The likelihood and form of somatic mutation is determined by the 
precise location of germline mutation of APC (Lamlum et al, 1999). 
 
1.1.2 Genotype-Phenotype correlation in FAP 
 
A genotype-phenotype correlation in FAP is well documented.  An APC 
mutation around codon 1300 is shown to be associated with severe 
phenotype, the patient having a high polyp burden and increased risk of 
colorectal cancer at early age (Groves et al, 2002). Clustering of somatic 
mutations has also been demonstrated in the APC gene, with more than 60 
per cent clustered in an area corresponding to less than ten percent of the 
coding region, also called the mutation cluster region (MCR) (Miyoshi et al, 
1992). This region corresponds to area between codons 1250 and 1450 on exon 
15 of the APC gene, and is also a common site of germline mutations. 
Germline mutations 5’ of codon 160 and 3’ of codon 1450 are associated with 
an attenuated colorectal phenotype, with later onset of more scanty 
adenomas, usually less than 100 in numbers (Will et al, 2008). 
 
Similar genotype-phenotype correlation has been described in some 
extracolonic manifestations of FAP. A far 3’ APC mutation predisposes to 
desmoid development and is associated with a higher incidence of sebaceous 
cyst, osteoma and more severe upper gastrointestinal polyposis 
(Nieuwenhuis et al, 2008; Wallis et al, 1999). Figure 1.1 demonstrates some of 
the common genotype - phenotype correlations in FAP. 
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Fig 1.1 – APC genotype-phenotype correlations in FAP (Adapted from Church J. 'Hereditary 
colorectal cancer' Chapter in The ASCRS Textbook of Colon and Rectal Surgery) 
 
1.1.3 Extra–colonic manifestations of FAP 
 
The broad expression of APC gene throughout human body and its multiple 
functions makes FAP truly a multi-system disorder. Increased incidence of 
hepatoblastoma and medulloblastoma have been reported in FAP patients 
(Kingston et al, 1983; Kropilak et al, 1989). Similarly, extracolonic cancers such 
as of gall bladder, thyroid, pancreas and adrenal gland have also been 
described (Bombi et al, 1984; Giardiello et al, 1993; Painter et al, 1985). Benign 
extracolonic manifestations associated with FAP include isolated or multiple 
osteomas of the mandible and skull, epidermoid cysts of the skin, dental 
abnormalities including accessory teeth, and congenital hypertrophy of 
retinal pigment epithelium (CHRPE). Desmoid tumours are benign but 
locally invasive tumours associated with FAP and are discussed in detail in 
section 1.2. 
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1.1.4 Clinical management of FAP 
 
FAP predisposes to the development of multiple colorectal adenomas with 
inevitable progression to cancer. Therefore the current management of FAP 
aims to offer prophylactic surgery.  Majority of the FAP patients are currently 
managed in institutions with dedicated polyposis registries. Studies have 
shown such management approach improves the prognosis of patients while 
compared to those who are treated outside the registry (Bulow et al, 1996). 
Registering individuals and families in the dedicated registries allows for 
accurate tracing and better screening of non-index cases.  
 
Members of known FAP family are first offered genetic screening test to 
detect APC mutation. Such screen detected FAP patients undergo 
prophylactive surgery, either colectomy with ileo-rectal anastomosis (IRA) or 
restorative proctocolectomy (RPC), during their late teens or early twenties.  
Patients with a MCR mutation (codon 1250 to 1450), 500 or more colonic 
polyps or twenty or more rectal polyps at diagnosis are usually offered RPC. 
Patients with milder phenotype of FAP (germline mutation 5’ of codon 160 or 
3’ of codon 1450) and low rectal polyp burden are usually offered IRA. 
However, it has been suggested that the penetrance for colorectal cancer is 
less than 100 per cent in the latter group of patients and some of these patients 
may be managed endoscopically, without the need for prophylactic surgery 
(Sinha et al, 2010).  
 
Following surgery, patients are regularly checked for polyp development in 
the rectum (IRA) or ileal pouch (RPC) with six monthly and yearly flexible 
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endoscopy respectively. Polyps detected during surveillance are usually 
treated with endoscopic ablation therapy. Pharmacological agents, 
particularly NSAIDs (Celecoxib, Sulindac) have also been shown to have a 
role in delaying polyp progression. Surgery is primarily reserved for 
increased polyp burden and unfavorable histology findings. 
 
Gastric polyps found in FAP are usually non pre-malignant and do not pose 
clinical issue. However, management of duodenal adenomas, which can 
progress to cancer, is challenging and based on the Spigelman scoring system 
(Spigelman et al, 1989).  This system classifies duodenal polyposis into four 
stages based on polyp number, maximum polyp size, degree of dysplasia and 
polyp histology. Stage I and II disease is managed with endoscopic 
surveillance alone while stage III disease is usually managed with therapeutic 
endoscopy. Duodenectomy is generally considered for stage IV disease. 
 
1.2   Desmoid Tumour 
 
1.2.1 Nomencleture and epidemiology 
 
Desmoid tumours (DT) are mesenchymal tumours originating from the 
musculoaponeurotic structures throughout the body. They can occur 
sporadically or in association with FAP.  The term ‘desmoid’ was coined from 
Greek word ‘desmos’, which means tendon like. Various other terminologies 
such as aggressive fibromatosis, deep fibromatosis and musculoaponeurotic 
fibromatosis have been used to describe these tumours in the past. 
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Desmoid tumours are rare and account for only 0.03% of all neoplasm 
(Caspari et al, 1995). The overall estimated annual incidence of desmoid is 2-5 
per million population (Reitamo et al, 1986). However FAP patients are about 
1000 time more likely to develop these tumours compared to the general 
population (Gurbuz et al, 1994) and the lifetime incidence of desmoid tumour 
in FAP patients is between 10 to 25 percent (Bertario et al, 2001). 
 
1.2.2 Desmoid in FAP 
 
Desmoids are locally infiltrative tumours but, unlike cancer, do not 
metastasize distantly. In post-colectomy FAP patients, desmoids are the 
leading cause of morbidity and mortality (Clark et al, 1999). In a series of 
studies published from St Mark’s Hospital, an Italian registry and the 
Cleveland Clinic, desmoids have ranged from the second to the third 
commonest cause of death in FAP patients (Nugent et al, 1993; Arvanitis et al, 
1990; Bertario et al, 1994). Additionally these tumours affect patients at a 
young age, with an average age of death reported to be 35 years in these 
studies. Figure 1.2 shows a large desmoid tumour in a patient with FAP. 
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Fig 1.2 – Intra-operative image of desmoid tumour in FAP (Image courtesy of Professor Robin 
Phillips, St Mark’s Hospital) 
 
FAP associated desmoids are genetically and biologically different from 
sporadic desmoids; FAP desmoids have mutation in the APC gene but the 
majority of sporadic desmoids have mutation in the gene encoding β-catenin 
(CTNNB1) (Lazar et al, 2008). Sporadic desmoids frequently occur in 
extremities and along the axial skeleton whereas FAP associated desmoids 
show propensity for intra-abdominal sites, especially the small bowel 
mesentery, and abdominal wall. About 70% of FAP associated desmoids are 
intra-abdominal. 
 
The clinical course of desmoid tumours is variable: 50% show a stable course, 
30% exhibit cycles of growth and regression, 10% resolve spontaneously and 
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10% progress rapidly (Church J, 1995). The rarity of the tumour coupled with 
its variable course makes meaningful research into desmoid tumour vary 
difficult. Many studies described in the literature have combined both 
sporadic and FAP associated desmoids to increase the sample size. However, 
all the studies described in this report are purely based on FAP related 
desmoid. 
 
1.2.3 The Wnt signalling pathway and desmoid tumour 
 
The principle role of APC as tumour suppressor is the regulation of the Wnt 
signalling pathway. Wnts are a family of secreted glycoproteins that 
modulate cell growth, differentiation and morphogenesis during 
development. However, abnormal activation of Wnt signalling also leads to 
cancer development (Sugimura and Li 2010).  
 
The Canonical Wnt signalling pathway has been extensively studied. Its 
primary role is stabilisation of cytosolic β-catenin. In the absence of Wnt 
signalling, normal APC forms a protein complex with AXIN and GSK-3b and 
promotes degradation of β-catenin (Bienz 2002). Binding of Wnt on the cell 
surface disrupts the β-catenin degradation complex resulting in the 
accumulation of β-catenin in the cytoplasm. The β-catenin molecules 
subsequently move to the nucleus and activate Wnt pathway transcription 
factors (Moon et al, 2004).  
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Fig 1.3 - Diagram depicting the canonical Wnt signalling pathway 
 
APC and β-catenin mutations (CTNNB1) have been analysed in both sporadic 
and FAP associated desmoid tumours. Most FAP associated desmoid tumour 
show a second hit somatic mutation of the APC gene. Prior studies of the 
secondary somatic mutations that occur in colonic adenomas from FAP 
patients revealed that the type and location of the somatic mutation were 
nonrandom and at least partially determined by the location of the germ-line 
mutation (Lamlum et al, 1999). The APC gene product contains seven 20 
amino acid β-catenin degradation repeats (AARs). These repeat segments 
permit binding of β-catenin leading to its ultimate degradation. The ‘just 
right’ model of FAP tumorigenesis proposes that there is an ideal level of      
β-catenin binding suitable for adenoma progression to colon cancer, and 
selective pressure results in nonrandom selection of somatic mutations 
resulting the appropriate number of AARs (Albuquerque et al, 2002). 
Analysis of FAP associated desmoid tumours by Latchford et al revealed that 
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87% (26/30) of tumours had one allele with no AARs and preferentially 
retained a total of two AARs 57% (17/30) (Latchford et al, 2007). These 
authors suggested that specific levels of β-catenin activity are required by the 
different tumour types, with desmoids preferentially requiring two AAR 
segments. A large Japanese study (86 colorectal tumours, 40 extracolonic 
tumours) identified similar associations between AARs and phenotype. With 
respect to FAP associated desmoid tumours, 5 of 6 were found to have two 
AARs in the Japanese study (Miyaki et al, 2008). 
 
 The majority of sporadic desmoid tumours harbour β-catenin mutation 
producing stabilized product not degradable by the APC, AXIN and GSK-3b 
complex.  Due to abnormal APC or β-catenin products resulting from these 
mutations, canonical Wnt signalling is thought to be constitutively activated 
in desmoid tumours. Increased β-catenin protein and β-catenin binding to 
TCF-3 have been described in sporadic desmoid tumours (Tejpar et al, 2001).  
 
Non-canonical Wnt signalling pathway is mediated by specific Wnt ligands 
and is independent of β-catenin. Apart from its role of antagonising canonical 
Wnt signalling, the non-canonical Wnt pathway is thought to regulate cellular 
motility and polarity. Further description of these pathways and laboratory 
based studies to establish activation of these pathways in a cell line from FAP 
associated desmoid tumour is detailed in chapter 10. 
 
	   38	  
1.2.4 Cell of origin 
 
Considerable debate existed for long time regarding whether desmoids 
represented simply a reactive process similar to wound healing or whether 
they were true neoplasms. Two studies in late 1990’s have firmly confirmed 
that desmoid is a clonal proliferation and hence represents a true neoplasm 
(Li et al, 1996; Middleton et al, 2000). 
 
Although now agreed as a neoplastic process, the cell of origin of desmoids 
still remains unidentified. Using an animal model Wu et al recently 
demonstrated that mesenchymal stem cells (MSC) and desmoids had similar 
gene expression profiles, and mice deficient in MSCs but prone to desmoids 
(mice with APC mutation and deficient MSC production) developed fewer 
desmoid tumours while gastrointestinal adenoma rates were unaffected. In 
fact, desmoid development in the mouse was directly proportional to the 
number of MSCs present. Additionally, MSCs with the APC mutation from 
heterozygote Apcwt/1638N mice produced DTs when transplanted to 
immunodeficient mice, but MSCs without mutation did not. Furthermore 
they found that MSCs from mice with inducible expression of β-catenin 
(Catnbtm2kem mice) could also induce desmoid-like tumours when transplanted 
to immunodeficient mice. Finally, they showed that these tumours were 
clonally derived from the donor MSCs with use of a green fluorescent protein 
tag (Wu et al, 2010).  
 
In another study, Carothers et al analysed 16 human desmoid tumours (8 FAP 
associated desmoids and 8 sporadic desmoids) using immunohistochemistry 
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and found that desmoid tissue expressed MSC markers but surrounding 
normal tissue did not. They next developed a primary desmoid cell line from 
the human desmoid tissue (FAP associated desmoid) and showed that the 
cells had an immunohistochemical profile consistent with MSC, and were 
able to differentiate into chondrocytes, osteocytes, and adipocytes, confirming 
that they were MSCs. These human desmoid derived MSCs were found to 
have elevated β-catenin in the nuclei (similar to desmoid tissue) and 
demonstrated up-regulation of Notch and Hedgehog pathways (Carothers et 
al, 2012). Although these studies do not definitely prove that the MSCs are the 
cell of origin of desmoid tumour in FAP, they do demonstrate the importance 
of MSCs in desmoid development. 
 
Many other studies have shown that majority of the cells in desmoid tumours 
are myofibroblasts (Kiryu et al, 1985; Gabbiani, 1996). Using primary cell lines 
established from desmoid tumours from FAP patients, Sinha et al 
demonstrated ubiquitous expression of cytoplasmic α-SMA in these cell lines, 
further suggesting myofibroblastic nature of these cells (Sinha et al, 2010). 
 
1.2.5   A model for desmoid development 
 
In 1998 Clark et al proposed a model for intra-abdominal desmoid tumour 
development and progression, which is analogous to the adenoma-carcinoma 
sequence in colorectal cancer. According to this model, a plaque like area of 
peritoneal thickening, ‘Desmoid Precursor Lesion (DPL)’ which is 
histologically compatible with desmoid can form in FAP patients due to 
abnormal fibroblast function. These DPL may progress to ‘mesenteric 
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fibromatosis’ (perhaps in some cases by surgical trauma) causing puckering 
and tethering of small bowel. In some patients this fibromatosis subsequently 
progresses to solid mesenteric desmoid tumour (Clark et al, 1998). This model 
was subsequently validated by Middleton et al using a CT scoring system in 
asymptomatic patients with FAP. This study demonstrated higher rate of 
mesenteric fibromatosis and desmoid formation in patients with previous 
DPL in comparison to control subjects (Middleton et al, 2003).  
 
1.2.6   Desmoid tumour pathology 
 
Macroscopically, desmoids tend to be large firm tumours with a coarse 
trabeculated surface. They may appear to be scar-like and encapsulated but 
frequently infiltrate adjacent tissue structures. Histologically, desmoids are 
characterised by mature highly differentiated fibroblast in an abundant 
collagen matrix containing blood vessels. The fibroblasts have a propensity to 
concentrate at the periphery of the lesion, and the cellularity is low. There are 
usually few mitotic figures and necrosis is usually absent. 
 
1.2.7 Anatomical distribution of desmoid tumour in FAP 
 
Desmoid tumours can arise at any site but more often arise in 
musculoaponeurotic structures. According to site of origin, these tumours can 
be divided into intra-abdominal desmoids (IAD), abdominal wall desmoids 
(AWD) and extra-abdominal desmoids (EAD). While sporadic desmoids 
occur primarily in extra-abdominal sites, the FAP desmoids show propensity 
to develop intra-abdominally and in abdominal wall. 
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1.2.7.1 Intra-abdominal desmoids 
 
Fifty to seventy percent of FAP desmoids are intra-abdominal primarily 
originating from the small bowel mesentery (Clark et al, 1999). Other intra-
abdominal sites described include transverse mesocolon, retroperitoneum 
and ligamentum teres (Burke et al, 1990). Due to their infiltrative nature, IAD 
are likely to cause mesenteric ischaemia, small bowel obstruction or 
perforation and ureteric obstruction. IAD are the major cause of morbidity 
and mortality in FAP patients with desmoid disease. Occasionally these 
tumours present with an air-fluid level on cross sectional imaging. A study 
into this rare presentation of IAD is detailed in chapter 6. 
 
1.2.7.2 Abdominal wall desmoids 
 
Abdominal wall desmoids are less problematic than IAD and are usually 
amenable to surgical excision, although have a high recurrence rate of over 
40%. AWD account for around 15% of desmoid tumours in FAP. 
 
1.2.7.3 Extra-abdominal desmoids 
 
These include tumours occurring outside the abdominal wall and abdominal 
cavity and account for about 15% of FAP associated desmoid. Common sites 
include the musculoaponeurotic planes of thoracic wall, the back and 
paraspinal muscles. EAD developing in the breast, head and neck region and 
palm of hands have been described in the literature. 
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1.2.8 Risk factors for desmoid in FAP 
 
 
 
The precise aetiology of FAP associated desmoids remains unknown. 
However various risk factors have been described in the literature. The 
implicated risk factors in desmoid include hormonal influences, surgical 
trauma, genetic predisposition and family history.  
 
1.2.8.1 Hormonal influence  
 
The female sex hormone oestrogen has long been implicated in pathogenesis 
of desmoid tumour. This stems largely from studies in sporadic desmoid 
tumour, where females of childbearing age were found to have the highest 
incidence of tumour (Reitamo et al, 1982). Other studies have demonstrated 
high levels of oestrogen receptors (ER) and antiestrogen binding sites (AEBS) 
in desmoid tumours (Sutherland et al, 1980; Lim et al, 1986).  
 
More recent studies have found variable effects of sex steroids in FAP 
associated desmoid. A study by Church et al found that pregnancy 
ameliorated the course of IAD significantly while compared to non-pregnant 
female controls (Church JM and McGannon E, 2000). In contrast to this study, 
Nieuwenhuis et al found an increased risk of AWD formation following 
pregnancy (Nieuwenhuis et al, 2008). A few other studies have failed to 
correlate a change in desmoid status with pregnancy (Clark et al, 1999; Mulik 
et al, 2003). 
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A recent meta-analysis combining seven studies evaluating over 2500 FAP 
patients with 388 desmoid tumours, however, found that females were one 
and half times more likely to develop desmoids compared to male patients 
(Sinha et al, 2010). 
 
1.2.8.2 Trauma 
 
Excessive adhesions and uglier scars following similar surgery have long 
been observed in patients with FAP (Lockhart-Mummery, 1967). Similarly, 
desmoids have been associated with many surgical wounds, including the 
sites of laparotomy, thoracotomy, laparoscopy and cesarean section. 
 
A study by Clark et al, looking for the presence of ‘desmoids precursor 
lesions’ in the mesentery of FAP patients undergoing laparotomy, detected 
such lesion in many patients without prior abdominal surgery. These lesions, 
however, were more advanced resulting in ‘mesenteric fibrosis’ in patients 
who had prior laparotomy. The author thus concluded that the trauma of 
surgery might have caused a precursor lesion to advance in stages to become 
a true tumour (Clark et al, 1998). A review of studies by same author further 
noted that over 70% of abdominal wall and intra-abdominal desmoids in FAP 
patients occurred after abdominal surgery with the majority occurring within 
first five years (Clark et al, 1996). In a recent meta-analysis of FAP patients 
with desmoid tumour, Sinha et al reported a threefold increased risk for 
developing desmoid tumour in FAP patients who had undergone previous 
abdominal surgery compared to those without previous operation (Sinha et 
al, 2010).  
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While the majority of the evidence suggests that FAP related desmoids, 
particularly AWD and IAD, occur following surgery, a study from the 
Cleveland Clinic has reported detection of IAD in four percent of patients 
during primary surgery for FAP (Hartley et al, 2004). 
 
1.2.8.3 Genetic predisposition 
 
Development of desmoids among individuals with FAP has long been 
correlated with specific APC mutations. Caspari et al first described that 
patients with APC germline mutation 3’ to 1444 had an increased 
predisposition to desmoid tumour (Caspari et al, 1995). Further studies with 
small numbers of FAP patients with desmoid tumour suggested that germline 
mutations in these patients tended to occur at the 3′ end of the gene (Dobbie 
et al, 1996; Wallis et al, 1999). Bertario et al from the Hereditary Colorectal 
Tumor Registry in Milan analysed 809 FAP patients with 107 DTs and 
reported a 12-fold increased risk of DT when the APC mutation occurred 3' of 
codon 1444, as compared with upstream mutations (Bertario et al, 2001). They 
found that genotype was the strongest predictor of desmoid development in a 
multivariate analysis. In a further study of 320 FAP patients with 50 DT from 
St Mark’s Hospital, Sturt et al reported a sevenfold increase in the odds of 
presenting with desmoid tumours in patients harbouring germline mutation 
3’ of codon 1399 (Sturt et al, 2004). In a recently published meta-analysis 
combining all the relevant previous studies (2098 FAP patients and 300 DT), 
Sinha et al have reported that a germ line mutation 3' to codon 1399 increased 
the odds for desmoids development in FAP patients by four times (Sinha et 
al, 2010).  
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The normal APC gene product contains seven 20 amino acid β-catenin 
degradation repeats (AARs) which bind and downregulate β-catenin. The 
number of these AARs remaining in the truncated APC protein has been 
shown to have functional importance, with desmoid development 
preferentially requiring two AARs segments. A combination of ‘first’ and 
‘second’ hit mutations is the important factor in providing this optimal level 
of β-catenin dysregulation. In APC gene the codon 1399 lies immediately after 
the second 20 amino acid β-catenin binding repeat.  Thus in patients with 
germline mutation 3’ to codon 1399 loss of heterozygocity (LOH) occurs 
spontaneously at a relatively high frequency, resulting in a more severe 
desmoid disease (Sturt et al, 2004).  
 
1.2.8.4 Family history and the role of modifier genes 
 
Eccles et al first described a variant of FAP, termed hereditary desmoid 
disease, in 1996. They reported 100% penetrance for desmoid tumour in three-
generation kindred with mutation at the extreme 3’ end of the APC gene and 
argued for a role for modifier gene in this family, as such total penetrance of 
desmoids is rarely seen in other families with 3’ mutation (Eccles et al, 1996). 
There are also reports of families with 5’ germline mutation and a high 
proportion of members affected with desmoids, further highlighting the role 
of possible modifier gene in such families (Sturt et al, 2006). Combining two 
separate studies (Bertario et al, 2001; Sturt et al, 2004) in a meta-analysis, 
Sinha et al found that a patient with positive family history of desmoids is 
seven times more likely to develop DT. This risk is independent of the site of 
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the germline mutation, suggesting a role for modifier genes in desmoid 
tumour development in such families (Sinha et al, 2010). 
 
 
1.2.9 Clinical features of desmoid in FAP 
 
 
Desmoid tumours display a variable clinical course. The majority of tumours 
may remain stable or even regress, with only ten percent growing relentlessly 
to cause major morbidity or mortality in FAP patients.  
 
Intra-abdominal desmoid tumours may remain asymptomatic until their 
growth and infiltration cause visceral compression or vascular compromise. 
Symptoms of intestinal obstruction or small bowel ischemia due to 
involvement of the superior mesenteric artery may be the first manifestation 
of IAD. Retroperitoneal extension causing ureteric compression and 
hydronephrosis or neural involvement may be another presenting feature. 
Rarely IAD can present with sepsis with an air-fluid level detected on cross 
sectional imaging, either due to necrosis of tumour or fistulation into viscera. 
Fig 1.4 shows an example of IAD with air-fluid level on CT scan.  
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Fig 1.4 – Intra-abdominal desmoid with air-fluid level (arrow) 
 
Abdominal wall desmoids and extra abdominal desmoids are less 
troublesome and are usually asymptomatic. They mostly present with 
complaints of cosmesis. However some AWD may infiltrate into the 
peritoneal cavity resulting in abdominal symptoms. Similarly EAD may 
present with functional deficits depending on their anatomical location. 
 
1.2.10   Imaging of desmoid tumours  
 
 
The majority of desmoids are clinically evident as palpable mass at 
presentation. Imaging is used primarily to confirm the diagnosis, to establish 
the relationship of tumour to surrounding structure before surgical excision, 
to assess tumour progression and monitor for complication. 
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1.2.10.1   Computed tomography 
 
Computed tomography (CT) scanning is currently the standard technique for 
assessing suspected intra-abdominal desmoid tumours in FAP and has also 
been widely used to evaluate desmoids at other sites (Healey et al, 1997). At 
CT, desmoids are seen either as ill-defined or well-circumscribed masses. 
Without contrast, these tumours show variable attenuation relative to muscle. 
With contrast, desmoid tumours may or may not appear enhanced. Einstein 
et al conducted a study on 34 desmoids (17 abdominal wall desmoids, 14 
mesenteric desmoids and 3 retroperitoneal desmoids) in 25 patients using 
contrast enhanced CT scan and reported that more than two thirds of such 
lesions had well defined borders with the majority showing attenuation equal 
to or greater than of surrounding muscle (Einstein et al, 1991). Fig 1.5 
demonstrates a typical appearance of desmoid tumour on contrast enhanced 
CT scan. 
 
 
Fig 1.5 – Contrast enhanced CT scan demonstrating three desmoid tumours (asterisks) 
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Computed Tomography is routinely performed nowadays using a 64-slice 
multidetector CT (MDCT) system. This system acquires 64 overlapping 0.6 
mm slices per rotation, resulting in great improvement in spatial resolution. 
CT, however, incurs a high radiation exposure. A study comparing the role of 
modern CT and MRI in assessment of FAP desmoid is further discussed in 
chapter 3. 
 
1.2.10.2     Magnetic Resonance Imaging 
 
Magnetic resonance imaging (MRI) is a well-established imaging modality for 
investigating soft tissue tumours. It avoids radiation exposure and is 
currently considered gold standard technique for the diagnosis and 
prognostication of benign and malignant soft tissue tumours, as well as rectal 
cancer (Tuncbilek et al, 2005).  
 
In MRI, desmoids are seen as masses of low signal intensity relative to muscle 
on T1 weight images while signal intensity on T2 weighted image is variable 
(low, intermediate or high) (Casillas et al, 1991). Fig 1.6 demonstrates typical 
T1 and T2 weighted images of desmoid tumours in a patient with FAP. 
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 a           b 
 
 
 
Healey et al studied 35 FAP associated desmoids using CT and MRI and 
reported that CT detected more intra-abdominal desmoids compared to MRI 
and was also more effective in showing the relationship of IAD to the bowel. 
In their study eight desmoid tumours with high signal intensity on initial T2 
weighted images showed significant growth on the follow up scans. Based on 
this finding they concluded that the high signal intensity on T2 weighted MRI 
was associated with aggressive desmoid behaviour (Healey et al, 1997). 
 
MRI techniques have significantly improved since the study by Healey et al. 
Modern day 1.5T MRI provides better soft tissue resolution. Furthermore 
advanced MRI imaging techniques such as diffusion tensor imaging (DTI), 
which assesses diffusion of water molecule in the tissue, and dynamic 
contrast enhanced imaging (DCE-MRI), which assesses vascularity of the 
tissue, are gaining increasing use in clinical practice. These advanced MRI 
Fig 1.6 - Typical appearances of desmoid tumour in T1 weighted (stars, a) and T2 
weighted (arrows, b) MRI. Variable signal intensity of these tumours is quite 
obvious in the T2 weighted MRI 
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techniques provide more functional information and further insight into 
tumour biology and behaviour.  Studies using these imaging modalities to 
characterise desmoid tumours and assess their behaviour are described in 
chapters 4 and 5. 
 
1.2.10.3    Positron Emission Tomography  
 
Positron emission tomography (PET) is a functional imaging method which, 
in combination of traditional imaging such as CT or MRI, serves as in vivo 
method of evaluating metabolism and physiology in normal and diseased 
tissue (Aoki et al, 2003). 18 F 2- Deoxy -2- fluoro-D- glucose (FDG) is the most 
commonly used radiolabelled tracer for PET and is widely used in oncology 
practice to detect the recurrence or metastasis of many cancers and also to 
evaluate the response to therapy (Visioni et al, 2011).  FDG–PET is also 
effective in differentiating between benign and malignant soft tissue tumours 
(Griffeth et al, 1992). 
 
There are limited reports of use of FDG-PET in assessment of desmoid 
tumour.  Souza et al described a case of chest wall desmoid tumour in 72-
year-old female with previous history of esophageal cancer and breast cancer. 
In this study low level of tracer uptake by the tumour and its well defined 
appearance helped them to determine the benign nature of the mass 
preoperatively (Souza et al, 2010). In a study of five patients with desmoid 
tumours using FDG PET, Basu et al reported that the FDG uptake by these 
tumours was heterogeneous. In this study, high avidity for FDG uptake was 
found in an aggressive recurrent desmoid tumour that was subsequently 
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treated with chemotherapy. The treatment response to chemotherapy was 
reflected in decreased FDG uptake in repeat PET CT (Basu et al, 2007). Makis 
et al have recently described a desmoid tumour of the colon mimicking 
colonic malignancy due to its high FDG avidity on PET CT (Makis et al, 2012). 
These studies have highlighted a potential role of FDG PET in assessing 
desmoid tumour aggressiveness, tendency to recurrence and response to 
therapy. A study combining functional MRI scan and FDG PET to assess 
biological behavior in FAP desmoids is described later in chapter 5. 
 
Recent years have also seen the increasing use of 18 F fluorocholine based 
PET in the imaging of different cancers (Mertens et al, 2010). This has 
stemmed from detection of increased choline metabolism in many cancer 
cells. Choline metabolism in desmoid tumour has not been studied. Increased 
choline metabolism in desmoid may provide a foundation for exploring the 
use of choline based PET in assessment of tumour behaviour. A study of 
choline metabolism using in-vitro model of desmoid tumour is detailed in 
chapter 9.  
 
1.2.10.4    Ultrasound scanning in desmoid tumour 
 
Desmoid tumours typically appear as homogenous anechoic or hypoechoic 
masses on ultrasound scanning. In the management of FAP patients, 
ultrasound is frequently used to monitor the progression of desmoid disease, 
particularly for the assessment of hydronephrosis caused by IAD. It is used to 
help guide the biopsy needle during percutaneous biopsy of AWD and IAD 
and also for percutaneous drainage of IAD presenting with an air-fluid level 
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and sepsis. Wang et al have recently described US-guided high intensity 
focused ultrasound (HIFU) as an effective minimally invasive therapy for 
local control of extra-abdominal desmoids (Wang et al, 2011). 
 
 
1.2.11   Treatment of desmoid tumour 
 
 
 
Treatment of desmoid tumour is complex and controversial. Following 
diagnosis, small asymptomatic desmoid tumours may simply be observed 
with regular clinic follow up, with or without imaging. Treatment is usually 
warranted for symptomatic patients or patients with rapidly growing 
tumours. The available options for treatment are pharmacological treatment 
(non-steroidal anti-inflamatory drugs (NSAIDs) and /or anti-estrogen), 
chemotherapy, surgical excision and/or radiotherapy. However there is lack 
of high quality evidence in the literature on which to base these treatments. 
The natural history of the disease, with some tumours showing spontaneous 
regression without any treatment, poses additional difficulty for evaluation of 
efficacy of one particular treatment.  
 
1.2.11.1   Pharmacologic treatment 
 
1.2.11.1.1  Non-cytotoxic drugs 
 
NSAIDs have long been used in patients with desmoids with varying success. 
Sulindac, indomethacin and celecoxib are the commonly used NSAIDs. These 
agents are either used alone or in combination with anti-estrogen. An early 
case report found that indomethacin used at 100mg/day orally provided a 
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rapid resolution of the desmoid tumour (Waddell et al, 1980). Tsukada et al 
used sulindac in 14 patients with a history of FAP and recurrent abdominal 
desmoid tumour and reported an overall response rate of 57%, however 
many of these responses were typically delayed by 24 months (Tsukada et al, 
1992).  
 
Tamoxifen is the most commonly used anti-oestrogen agent to treat desmoid 
tumour. Other agents used include toremifene and raloxifene. Hansmann et 
al conducted a study using high dose tamoxifen (120mg/day) and sulindac 
(300mg/day) and reported no tumour growth in three out of eight patients 
with sporadic desmoids and 10 out of 13 patients with FAP associated 
desmoids (Hansmann et al, 2004).  In a recently published systematic review, 
anti-estrogen therapy was found to be effective in about 50% of patients 
irrespective of whether the tumours were primary or recurrent, or sporadic or 
FAP related. Interestingly no added advantage was conferred by combining 
anti-estrogen with NSAIDs (Bocale et al, 2011). 
 
Other drugs that have been used to treat desmoids include glocucorticoids, 
interferon alpha, cyclic AMP inhibitors, anti-fibrinolytic agent pirfenidone, 
and the tyrosine kinase inhibitor iminitab mesylate. However, the true 
efficacy of NSAIDs, anti-estrogen and other agents used to treat desmoid 
tumour is difficult to interpret due to variable course of the tumour, small 
number of patients included in these studies and the lack of randomised 
control trials. 
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1.2.11.1.2   Cytotoxic chemotherapy 
 
Despite the lack of any randomised trials cytotoxic chemotherapy for 
desmoid is relatively widely reported in the literature (Patel et al, 1993; 
Okuno et al, 2003). Both treatments with low-dose chemotherapy using 
vinblastin and methotrexate and, more commonly, a regimen based on 
doxorubicin and dacarbazine, have been described. Azzarelli et al have 
reported a sixty percent stable course with minor tumour shrinkage and 
symptom relief in thirty patients, after treatment with low doeses of 
vinblastin and methotrexate (Azzarelli et al, 2001).  Gega et al have described 
use of doxorubicin and dacarbazine followed by meloxicam, a cyclo-
oxygenase 2 (COX-2) inhibitor in seven FAP patients with symptomatic 
unresectable desmoid tumours. Significant tumour regression was observed 
clinically and radiologically in all seven patients, with three patients showing 
a complete response. The average progression-free survival period in this 
study was 74 months (range, 32.5 to 107.5 months) (Gega et al, 2006). 
 
The current practice at our institution is to use cytotoxic chemotherapy as a 
last resort in patients with inoperable aggressive desmoid disease where non-
cytotoxic treatment with a combination of non-steroidal and anti-estrogen has 
failed. 
 
1.2.11.2   Surgery for desmoid tumour 
 
Surgery for AWD and EAD is generally safe, however a high recurrence rate 
up to 45% has been reported (Heiskanen et al, 1996; Clark et al, 1999). 
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Nieuwenhuis et al recently reported a 63% progression free survival at ten 
years following excision of 14 AWD and EAD in FAP patients (Nieuwenhuis 
et al, 2011). 
 
Surgery for IAD is more problematic. A previous study from St Mark’s 
Hospital reported a perioperative mortality of 36% after excision of IAD 
mainly due to haemorrhagic complications. Nearly half of the surviving 
patients in this study needed extensive enterectomy resulting in the need for 
long-term parenteral nutrition. In addition, the tumour recurred in 71% of 
these patients (Clark et al, 1999).  
 
The surgical management of desmoid tumour, however, has changed over the 
last decade and many centres are now adopting a less aggressive surgical 
approach. More recently a wait and see approach to DTs has been advocated 
as many DT either show a prolonged stable phase or even spontaneous 
regression (Calvert et al, 2012).  
 
1.2.11.3  Newer treatment modalities in desmoid tumour 
 
Recently there have been increasing reports of radiologically guided targeting 
of desmoid tumours. A percutaneous chemical ablation of two desmoids (one 
intra-abdominal) using acetic acid under radiological guidance was first 
described by Clark TW. A complete response was achieved in one patient and 
a partial response was achieved in the other patient; these responses were 
sustained during two years of follow up (Clark 2003). 
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Tsz-Kan et al first described the use of radio frequency ablation (RFA) in 
treating a 47-year-old patient with recurrent desmoid tumour in the lower 
back. They reported no recurrence of tumour after 28 month using serial 
follow up MRI (Tsz-Kan et al, 2007). More recently IIaslan H et al described 
treatment of five EADs with RFA. None of the treated tumours recurred 
during a mean follow up of 30 months (range 4-68 months), however one 
patient developed cellulitis and another soft tissue necrosis following the RFA 
treatment (IIaslan et al, 2010). 
 
Kujak et al used percutaneous cryoablation in the treatment of five EAD in 
five patients including two FAP patients. In three tumours cryoablation was 
used for local control of disease following recurrence after multiple treatment 
with different modalities. In two tumours, cryoablation was primarily used to 
palliate the symptoms of pain caused by proximity or involvement of nerve 
or vessel by the tumours. All the patients treated for local control of disease 
had significant improvement in symptoms, with complete resolution of 
tumours in two patients and moderate decrease in tumour size in a third. 
Despite some reduction in the size of tumours, no significant symptom relief 
was achieved in palliative group using this modality of treatment (Kujak et al, 
2010). 
 
Ultrasound guided high intensity focused ultrasound treatment for extra- 
abdominal desmoids has been recently described by Wang et al. They have 
reported a significant shrinkage (>50% in volume) of all the treated tumour 
(n=25) during a mean follow up of 30 months (range 8-55 months) (Wang et 
al, 2011). 
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All these techniques described above, however, represent experience of 
individual groups treating small number of desmoid tumours. While these 
initial results may be promising, further research with larger patient numbers 
is needed to validate the potential role of any individual techniques in 
treating desmoids tumours.  
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Chapter 2 
 
 
Aims of work described in this thesis 
 
Desmoid tumours remain an outstanding challenge in the management of 
FAP patients. These tumours show a variable course with only ten percent 
growing relentlessly causing major morbidity and mortality. However no 
molecular, pathological or clinical marker of aggressive phenotype has yet 
been identified. Early identification of the desmoid that may behave 
aggressively could allow targeting of treatment to such patients early, 
preventing major morbidity and mortality. 
 
The studies described in this thesis characterise these tumours further and 
also aim to identify markers of aggressive phenotype by the use of modern 
imaging modalities. Treatment of aggressive intra-abdominal phenotype of 
desmoid is reviewed and a management algorithm developed. Laboratory 
based studies investigate choline metabolism and Wnt signalling pathways 
using a cell culture model of desmoid tumour. 
 
2.1 Imaging Studies 
 
The first imaging study described in this thesis compares the 64-MDCT to 
modern day 1.5T MRI for the assessment of FAP desmoids.  MRI spares the 
high radiation incurred by CT and is an important consideration while 
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imaging young patients with FAP and desmoids. Further study using 
diffusion tensor imaging (DTI) to evaluate its feasibility and explore its use in 
the assessment of desmoid tumour is described in a second study. The third 
study combined the metabolic (PET CT) and vascular imaging (DCE-MRI) 
and explores their potential role in predicting the behavior of FAP desmoid. 
 
2.2 Clinical study 
 
A clinical review of intra-abdominal desmoids presenting with air-fluid level 
on cross sectional imaging was carried out. The treatment in the tertiary care 
centre specialising in FAP desmoids was reviewed and a management 
algorithm was developed. 
 
2.3 Laboratory studies 
 
An in-vitro desmoid cell model was used for the laboratory studies described 
in this thesis. The first chapter describes the confirmation of desmoid tumour 
cell line by ‘second hit’ mutation analysis in the cells. A study to investigate 
the abnormal choline metabolism in desmoid tumour cells is described in the 
second chapter. Finally studies investigating the Wnt signalling pathways in 
desmoid tumour, by immunocytochemistry, immunohistochemistry, western 
blot, RT-PCR and qPCR, is described in the third chapter. 
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PART 2 – IMAGING STUDIES
	   62	  
Chapter 3 
 
 
 
 
A prospective comparision of 64-slice multidetector 
computer tomography and 1.5-Telsa magnetic resonance 
imaging in the assessment of desmoid tumours in 
familial adenomatous polyposis 
 
3.1 Background 
 
Cross-sectional CT is currently used as standard technique for evaluating 
desmoids in FAP (Sturt et al, 2006). Multi-detector computed tomography 
(MDCT) utilizes multi-planner reformatting images to accurately localize the 
site of pathology; 64 overlapping 0.6mm slices per rotation are acquired 
during 64-MDCT. This advanced technique results in better spatial resolution 
and elimination of spiral artifacts encountered by helical CT and is currently 
widely used in practice. However CT incurs a high radiation exposure. The 
typical effective dose of 64-MDCT is 15.2 millisieverts (mSv), which is 
equivalent to 760 plain chest X-ray (Baskerville, 2008). Furthermore 0.4% of 
cancer diagnosed in United States has been attributed to high radiation 
exposure from CT (Brenner et al, 2007).  
 
Magnetic resonance imaging (MRI), on the other hand, utilizes a strong 
magnetic field to acquire the images and hence avoids radiation exposure. 
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Due to its superior contrast to noise ratio, MRI is well established in the 
differential diagnosis and prognostication of many benign and malignant soft 
tissue tumour and cancers including rectal cancers (Tuncbilek et al, 2005). 
Intuitively MRI may provide better assessment of desmoids. Nevertheless, to 
date there have been few MRI data relating to FAP associated desmoids. 
Various case reports and small series have described the MRI features of 
desmoids (Souza et al, 2010; O’Keefe et al, 1990; Chummun et al, 2010; 
Castellazi et al, 2008), however, many of these combine sporadic and FAP 
related desmoids to maximise case numbers. Clinically this is less useful as 
FAP related desmoids differ from sporadic desmoids both in their clinical 
traits and biology. 
 
3.2  Aims of this study 
 
A previous study from St Mark’s Hospital comparing MRI and CT for 
assessing desmoids in FAP demonstrated that MRI can show both IAD and 
AWD in FAP patients, but the anatomical imaging by CT was superior. This 
study also showed high signal intensity on T2-weighted images to be 
predictive of aggressive desmoid behaviour (Healey et al, 1997). A typical 
appearance of an IAD diagnosed on MRI by Healy et al in 1996 is 
demonstrated in figure 3.1. Poor image resolution of this subtle pathology 
made interpretation difficult at that time. 
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Fig 3.1 - Typical image of intra-abdominal desmoid diagnosed by Healy et al on MRI in 1997 
(image courtesy of Miss Susan K Clark, St Mark's Hospital) 
 
Since this study, both CT and MRI technology and protocols have improved 
substantially. To the best of our knowledge no studies have compared state of 
the art MRI and MDCT. The aim of this study was to establish whether 
modern 1.5T MRI techniques provide equivalent or superior assessment of 
FAP associated desmoids to 64-slice MDCT.  
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3.3 Materials and methods 
 
3.3.1 Patient selection 
 
The St Mark’s Hospital Polyposis Registry database was searched to identify 
patients with a diagnosis of FAP, defined by either an identified APC 
mutation or the presence of over 100 colorectal adenomas with no evidence of 
MYH mutation. FAP patients with confirmed desmoid tumour based on 
previous radiological and clinical evidence were identified and prospectively 
recruited. All patients underwent abdominal MDCT and MRI, with scans 
being performed within one month of each other.  
 
3.3.2 Regulatory approvals 
 
Ethical approval for this study was obtained from the Harrow Research and 
Ethics Committee (REC reference number: 07/H0719/100). Research and 
development approval and study management approval at St Mark’s 
Hospital and Paul Strickland Scanner Centre, Mount Vernon Hospital sites 
was obtained from the North West London Hospitals Research and 
Development Department (R&D reference number: RD7/090). Informed 
written consent was obtained from all recruited patients. 
 
3.3.3 Image acquisition 
 
MDCT was performed using a 64 MDCT scanner (Brilliance 64, Phillips 
Healthcare, Eindhoven, The Netherlands). Following IV contrast 
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administration (100ml at 3mls-1 via a pump injector; Visipaque 270 GE 
Healthcare, New Jersey, USA) and a delay of 65 seconds, imaging was 
performed using the parameters summarised in Table 3.1. 
 
 
MDCT  
Kv 
 
 
mA 
 
Rotation 
Speed 
 
Matrix 
 
FoV 
 
Collimation 
 
ST 
 
120 
 
280 
 
0.75 
 
512 
 
350 
 
64x0.625 
 
2mm 
 
 
Table 3.1 – Acquisition parameters for MDCT 
 
MRI was performed using a 1.5-Tesla MR scanner (Siemens Avanto, Siemens 
Healthcare, Erlangen, Germany) and multi-channel multi-element coil 
system. T1 and T2-weighted axial, coronal and sagittal sequences of the 
abdomen and pelvis were supplemented by short tau inversion recovery 
(STIR) and T1-weighted post gadolinium axial sequences. The acquisition 
parameters are listed in Table 3.2. Respiratory gating was used to reduce 
movement artifacts caused by breathing, and 10mg of intravenous hyoscine-
N-butylbromide (Buscopan; Boehringer Ingelheim, Ingelheim am Rhein, 
Germany) was used to reduce peristalsis.  
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1.5T-MRI 
 
TR 
 
TE 
 
FA 
 
TI 
 
ST 
 
NEX 
 
Matrix 
 
FoV 
 
 
T1 
 
200 
 
4 
 
70 
  
5 
 
1 
 
256/179 
 
70 
 
 
T2 
 
3180 
 
97 
 
150 
  
5 
 
1 
 
256/179 
 
150 
 
 
STIR 
 
3800 
 
93 
 
160 
 
150 
 
5 
 
1 
 
256/131 
 
160 
 
 
T1-post 
contrast 
 
195 
 
4 
 
70 
  
8 
 
1 
 
256/157 
 
70 
 
Table 3. 2 - Acquisition parameters for MRI 
 
3.3.4 Image analysis 
 
Two experienced gastrointestinal radiologists assessed the MDCT and MRI 
viewed on standard reporting workstations (Brilliance, Phillips Healthcare; 
Leonardo, Siemens Healthcare) on separate occasions. In case of discrepancy, 
consensus was reached via discussion. Abdominal MDCT was used as the 
gold standard for the identification of all IAD, AWD and EAD on MRI. 
 
3.3.5    Outcomes of interest 
 
For each modality the number of desmoids and desmoid tumour size was 
documented. The size of desmoids was obtained by automated region of 
interest analysis and the area recorded in cm2. All desmoid lesions were 
classified by site into IAD, AWD or EAD. IAD incorporated mesenteric 
desmoids; AWD incorporated desmoids located in anterior and posterior 
abdominal wall muscles; EAD incorporated desmoids at other sites. For each 
lesion its margin was noted on both modalities and its relationship to bowel, 
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urinary tract and vessels, including the proximal superior mesenteric artery, 
was recorded.  
 
3.3.5.1    Contrast enhancement ratio 
 
The enhancement ratio on each modality was calculated for each lesion by 
dividing the desmoid enhancement by the aortic enhancement. This ratio was 
compared between the two modalities. 
 
3.3.5.2    T2 signal intensity 
 
The signal intensity on T2-weighted images was defined in relation to muscle 
and water. Low signal intensity was less than or equivalent to that of muscle, 
intermediate signal intensity was greater than that of muscle but less than that 
of water, and high signal intensity was greater than or equal to that of water. 
If a lesion had mixed signal intensity but had a significant proportion of high 
signal intensity (50% or more), it was considered of high signal intensity. 
 
3.3.6 Statistical analysis 
 
Statistical analysis was conducted using STATA™ SE 10.1 for Macintosh 
(STATA Corp, Texas, USA). Desmoid tumour size is described as median and 
range; these were compared using Mann-Whitney U-test. Contrast 
enhancement ratios obtained by the two modalities were reported as mean 
value and standard deviation. These proportions were compared using 
Student’s t-test following test of normality. A p-value less than 0.05 was 
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considered statistically significant.  
 
Desmoids were stratified into two groups based on signal intensity on T2-
weighted images, those with high signal intensity and those with low or 
intermediate signal intensity. The mean MRI contrast enhancement ratio 
between these two groups was also compared using Student’s t-test.  
 
3.4  Results 
 
Nine patients with FAP and desmoid disease underwent MDCT and MRI 
within one month of each other. The demographic details of the included 
patients are described in Table 3.3. 
 
 
Patient 
 
Age at desmoid diagnosis 
(years) 
 
Gender 
 
APC mutation 
(codon) 
 
Surgery for FAP 
 
1 
 
26 
 
F 
 
1392 
 
IRA 
 
2 
 
43 
 
M 
 
1465 
 
RPC 
 
3 
 
50 
 
M 
 
1551 
 
RPC 
 
4 
 
22 
 
M 
 
1556 
 
IRA 
 
5 
 
34 
 
M 
 
1551 
 
RPC 
 
6 
 
24 
 
F 
 
1509 
 
RPC 
 
7 
 
32 
 
F 
 
1182 
 
IRA 
 
8 
 
24 
 
F 
 
213 
 
IRA 
 
9 
 
31 
 
F 
 
1444 
 
IRA 
 
 Table 3.3 - Demographics of included patients 
 
Twenty-three desmoids (9 IAD, 10 AWD and four EAD) were identified on 
MRI. Twenty-one desmoids (9 IAD, 9 AWD and three EAD) were identified 
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on MDCT. MRI identified two additional desmoids, one EAD and one AWD, 
which were not easily detected even on retrospective review of MDCT (Fig 
3.2, Fig 3.3).  
 
      
A      B 
Fig 3.2 - Contrast-enhanced CT (A) and T2 weighted MRI (B) demonstrating multiple 
desmoid tumours (asterisks). The extra-abdominal desmoid (EAD) shown on MRI (arrow) is 
difficult to identify on CT    
       
A      B 
Fig 3.3 - Contrast-enhanced CT (A) and corresponding T2 weighted MRI (B) of abdominal 
wall desmoid (AWD). This lesion was easily detected on MRI (arrow) and missed on CT 
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For the 21 lesions seen on both modalities, there was concordance with regard 
to desmoid size, site and extent of local infiltration margin. The contrast 
enhancement ratio for MRI was significantly greater than for MDCT. Table 3.4 
summarises the results of comparison between the two modalities. 
 
Size (cm2) 
  
Infiltration 
  
Enhancement Ratio DT 
  
Site 
  
 CT MRI Bowel Ureter SMA origin 
T2-signal 
  
 CT MRI  
1 IA 63 61 Yes Yes No Low  0.47 0.75 
2 AW 181 179       High 0.43 1.38 
3 IA 79 81 Yes Yes No Low 0.49 1.38 
4 IA 11 10 No Yes No Low 0.54  1.12 
5 EA 215 215       Low 0.5 1.24 
6 AW 28 27       High 0.48 1.81 
7 IA 74 72 Yes Yes No Low 0.49 0.75 
8 EA 41 39       Low 0.79 0.33 
9 AW 13 14       Low 0.69 0.99  
10 AW 49 51       High 0.66 2.17 
11 IA 85 84 Yes No No Low 0.7 0.66 
12 EA 15 14       High 0.53  0.87 
13 AW 5 4       Low 0.67  1.11 
14 IA 73 72 No No No Low 0.43 1.66 
15 AW 74 72 No Yes No High 0.25 1.26 
16 AW 5 7       Intermediate 0.38 1.07 
17 IA 126 126 No No No Low  0.37 0.88 
18 IA 22 21 Yes No No Low 0.25  0.91 
19 AW 3 4       Intermediate 0.19  0.89 
20 IA 26 27 No No No Low 0.36 0.72 
21 AW 2 3       High 0.38 1.55 
Median 41 39 Mean 0.479 1.12 
Range 
 
 
2 - 
215 
 
3 - 215  
 
Standard 
Deviation 
0.159 0.432 
P-value* 0.985 
 
 P-value§  <0.0001 
 
* Mann-Whitney U-test;  § Students t-test 
Table 3.4 – Summary of results 
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3.4.1   Intra-abdominal desmoids  
 
Nine IAD were identified, all localized to the small bowel mesentery. There 
was consistency between the two modalities in the assessment of number, site 
and local extent of these mesenteric desmoids. Five IAD involved the bowel; 
four resulted in extrinsic ureteric compression. While infiltration around 
mesenteric vessels was demonstrated on both scans, none compromised the 
proximal superior mesenteric artery. The median size of these IAD was 73 
(range, 11-126) cm2 on MDCT and 72(10-126) cm2 on MRI (p=0.98). For these 
IAD, the mean contrast enhancement ratio for MRI – 0.98(standard deviation, 
0.34) – was significantly greater than for MDCT – 0.46(0.13) (p=0.0005). All 
nine IAD had a low T2-signal intensity. 
 
3.4.2   Abdominal wall desmoids 
 
Nine AWD were identified, with both MDCT and MRI agreeing on desmoid 
number, site and local extent. The size of these AWD on MDCT – 13(2-181) 
cm2 – was equivalent to that on MRI – 14(3-179) cm2 (p=0.99). The contrast 
enhancement ratio on MRI – 1.36(0.42) – was significantly greater than for 
MDCT – 0.46(0.18) (p<0.0001). These AWD displayed variable T2-signal 
intensity, as described in Table 3.4. MRI identified one extra AWD that was 
difficult to identify even on retrospective review of MDCT due to its similar 
density to muscle (Fig 3.3). 
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3.4.3  Extra-abdominal desmoids 
 
Three EAD were detected by MDCT. MRI identified these lesions and one 
additional EAD, within the erector spinae muscle (Fig 3.2).  For the three EAD 
seen on both modalities, there was consistency regarding site and local 
infiltration. The size of these EAD on MDCT – 41(15-215) cm2 – was 
equivalent to that on MRI – 39(14-215) cm2 (p=0.98). The contrast 
enhancement ratio of these EAD on MRI – 0.81(0.46) – was not significantly 
different when compared to MDCT – 0.61(0.16) (p=0.50). These EAD had 
range of T2-signal intensity, as described in Table 3.4. The additional EAD 
detected by MRI displayed high T2-signal intensity and was thus conspicuous 
(Fig 3.2).  
 
3.4.4   T2-signal intensity and MRI contrast enhancement ratio 
 
The comparison between mean (standard deviation) MRI contrast 
enhancement ratio and signal intensity on T2-weighted images shows that the 
high signal intensity group had a significantly greater MRI contrast 
enhancement ratio compared to the low and intermediate group – 1.51(0.45) 
and 0.96(0.32) respectively (p=0.006). Figure 3.4 displays the comparison 
between T2-signal intensity and MR enhancement ratio.  
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Fig 3.4 – T2 signal intensity and MRI contrast enhancement ratio 
 
The MRI contrast enhancement ratio across the three anatomical sites for 
desmoids was – IAD 0.97(0.39), AWD 1.54(0.40) and EAD 0.79(0.46). No 
significant difference was detected between these three groups (p>0.05). 
 
3.5 Conclusions 
 
The results of this study demonstrate that MRI identified a greater number of 
desmoids than MDCT. MRI has been proven to be superior to CT in the 
assessment of soft tissue tumour heterogeneity due to its superior soft tissue 
contrast (Tunckbilek et al, 2005). There have been significant improvements in 
imaging technology since Healy et al (1997) compared CT and MRI for the 
assessment of desmoids in FAP. Our current study supports the use of 
modern day MRI for assessing desmoids in FAP patients.  
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3.5.1    Desmoid detection rate  
 
Healy et al detected 35 desmoids (22 IAD and 13 AWD) on CT compared with 
34 desmoids (21 IAD and 13 AWD) on MRI, giving a detection rate of 97% on 
MRI; no EAD were identified by either modality (Healy et al, 1997). In their 
study, there was one false positive diagnosis (the pancreatic head was 
misdiagnosed as a desmoid on MRI) and one false negative diagnosis (a 
desmoid was misdiagnosed as a loop of small bowel on MRI). 
 
In the current study 21 desmoids were detected (9 IAD, 9 AWD and three 
EAD) on MDCT and 23 (9 IAD, 10 AWD and four EAD) on MRI, giving a 
detection rate of 110% on MRI. The two additional desmoids detected by MR, 
whilst small in size, were of high T2-signal and more conspicuous. There 
were no false positive or false negative diagnoses. Advancements in modern 
day MRI technology, including better spatial resolution, particularly when 
utilizing breath-hold sequences, have enabled this superior detection rate. 
This is consistent with another study, where MRI was superior to CT in the 
assessment of soft tissue tumours due to its superior soft tissue contrast 
(Tunckbilek et al, 2005).  
 
Unlike the study by Healy et al where MRI was inferior to CT in delineating 
the extent of mesenteric desmoids, in our study both MDCT and MRI were 
equivalent in assessment of infiltrative extent of intra-abdominal desmoids, in 
particular small bowel and ureteric involvement. Both techniques were able 
to demonstrate disease around mesenteric vessels but the superior mesenteric 
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artery remained uncompromised in all patients, again reflecting 
improvements in MRI technology since Healy et al conducted their study.  
 
3.5.2    T2 signal characteristics and contrast enhancement ratio  
 
Healy et al also suggested that high signal intensity on T2-weighted images 
might be useful in identifying aggressive desmoids. In this study high signal 
intensity on T2-weighted images was associated with a significantly higher 
MRI enhancement ratio (in comparison to the low/ intermediate signal 
intensity group), suggesting that this may reflect greater cellularity and 
vascularisation of potentially aggressive desmoid tumours. The potential for 
signal intensity and MRI enhancement ratio as a surrogate for desmoid 
growth warrants further exploration. Nevertheless it should be borne in mind 
that this remains controversial as another study of aggressive fibromatosis 
(Castellazzi et al, 2008) has been unable to predict desmoid behaviour based 
on the MRI signal alone.  
 
3.5.3  Summary  
 
The major limitation of this study is the small number of patients available for 
analysis. However, FAP associated desmoid tumours are rare entities and this 
study does provide valuable prospective comparison between MDCT and 
MRI. These data suggest that MRI is clearly no worse than MDCT for the 
assessment of desmoids in FAP.  
In addition, the interpretation of both MDCT and MRI is operator dependant. 
Particularly, the detection of rare pathologies, such as subtle desmoids, relies 
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heavily on reader expertise. Currently, greater experience exists in assessing 
desmoids with CT than with MRI. As the learning curve for desmoid 
characterisation with MRI improves, and further evidence is accrued, MRI 
may feasibly become the primary modality in the future for assessing 
desmoids. However, both readers in this study were experienced 
gastrointestinal radiologists at a tertiary FAP centre.  
 
The MRI examination time was approximately 25 minutes, which is longer 
than CT but was well tolerated by the study patients. Generally young 
patients are able to manage the breath-holds required for MRI without 
difficulty. However, it can be a problem for some, resulting in reduced 
accuracy of MRI compared to CT in the assessment intra-abdominal 
relationships. No patient declined MRI and no one suffered claustrophobia 
during this study.  
 
FAP patients with IAD require periodic imaging to assess the disease status, 
to evaluate symptoms and to exclude complications (in particular silent 
ureteric obstruction) of desmoid disease. Current practice using CT scan 
potentially incurs a heavy radiation burden given the effective dose of 
10mSv/examination for abdominal pelvic CT. These patients are usually 
young. Hence, MRI is an attractive prospect due to its lack of radiation.  
 
In summary, this study has shown that MRI is at least equivalent to and may 
be superior to MDCT in the detection of desmoid tumours in patients with 
FAP, and supports the use of modern day MRI for assessing desmoids in 
patients with FAP.  
	   78	  
Chapter 4 
 
 
Diffusion tensor imaging (DTI) in the assessment of 
desmoid tumours in familial adenomatous polyposis 
 
4.1 Background 
 
The imaging appearance of desmoid tumour depends on the degree of 
fibroblastic proliferation, fibrosis, collagen content and vascularity. In MRI 
most abdominal wall or extra-abdominal desmoid tumours are well-
circumscribed homogeneous lesions, which appear isointense relative to 
muscle (O’Keefe et al, 1990). Intra-abdominal or mesenteric desmoids 
typically appear more infiltrative (Casillas et al, 1991). 
 
CT is performed most commonly for tumour assessment and to monitor 
growth (Einstein et al, 1991; Healy et al, 1997) but has its limitations in 
predicting tumour aggressiveness and growth rate. The potential of MRI in 
FAP as a primary assessment tool has been explored previously (Healy et al, 
1997): desmoid tumours may appear hypo- or isointense relative to muscle on 
T1-weighted sequences, while T2 signal intensity may be more variable, 
purported to be due the degree of fibrosis and cellularity: T2 hyperintensity 
has been suggested as an imaging marker of actively growing tumours (Healy 
et al, 1997), though data have been conflicting outside of FAP (Castellazzi et 
al, 2008). With improvements in MR systems and introduction of parallel 
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imaging technology, diffusion weighted studies within the abdomen and 
pelvis have become possible. Advanced MRI techniques that assess water 
diffusion, such as diffusion tensor imaging (DTI) may provide further 
information of the microstructure in particular its cellular and fibrous content 
(Manenti et al, 2007; Gurses et al, 2006; Takayama et al, 2008), and may 
potentially provide evidence of tumour aggressiveness.  
 
4.2 Diffusion Tensor Imaging  
 
Diffusion tensor imaging (DTI) is an advanced MRI technique that allows the 
mapping of the diffusion process of molecules, mainly water in biological 
tissue, non-invasively. Molecular diffusion in tissues is not free, but reflects 
interactions with many obstacles, such as macromolecules, fibres, membranes, 
etc. Water molecule diffusion patterns can therefore reveal microscopic 
details about tissue architecture. In general, in tissues without a well-ordered 
microstructure, the water molecules flow in an isotropic way, ie, in an 
identical way in the different spatial directions. On the other hand, in 
structures with a high degree of structural order, molecular diffusion has a 
preferential direction or anisotropy (Le Bihan et al, 2001). The magnetic 
resonance measurement of an effective diffusion tensor of water in tissues can 
provide unique biologically and clinically relevant information that is not 
available from other imaging modalities. 
 
DTI has long been successfully applied in the field of neuroradiology, 
particularly in the assessment of acute cerebral ischemia (Schaefer et al, 2000). 
Initially, DTI in other than intracranial sites did not yield sufficient image 
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quality due to susceptibility artefacts and motion artefacts. More recently, 
technical advances in MRI, such as the development of parallel imaging, high 
gradient amplitudes, and multichannel coils, have enabled the performance of 
DTI in the body. These developments have initiated the investigation of 
applicability of DTI for tumour characterisation, both intra- and extracranially 
(Vermoolen et al, 2012).  
 
Diffusion weighted images can be assessed in two ways, qualitatively, by 
visual assessment of signal intensity, and quantitatively, by measurement of 
the apparent diffusion coefficient (ADC). The ADC value quantifies water 
proton motion, which in biological tissues is a combination of true water 
diffusion and capillary perfusion. The ADC value can theoretically be used to 
characterise tissues, as the degree of diffusion is correlated to cellular density 
and extracellular space volume (Guo et al, 2002; Sugahara et al, 1999). 
Malignant tumours are reported to have a high cellular density and low 
extracellular space volume, which is associated with impeded water proton 
diffusion and low ADC values. In contrast, various benign lesions are 
characterised by an increased amount of extracellular matrix with minimal 
increase of cellular density, which may result in higher ADCs (Kwee et al, 
2008). Other parameters assessed in the DTI are Fractional Anisotropy (FA) 
and Relative Anisotropy (RA). FA describes the fraction of diffusivity that can 
be ascribed to anisotropic diffusion, and RA, the ratio of the anisotropy to 
isotropic part, may inform on the presence and degree of fibrosis, which may 
demonstrate higher directionality. 
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4.3 Aim of the study 
 
The aim of this exploratory study was to assess the feasibility and potential of 
DTI for desmoid tumour assessment in FAP. Given the unpredictable growth 
pattern of desmoid tumours in FAP patients, an imaging technique that may 
provide insight into the tissue microarchitecture may help to identify 
potentially aggressive tumours in order to tailor treatment at an earlier stage. 
 
4.4 Materials and methods 
 
4.4.1 Patient selection 
 
Nine patients with FAP and desmoid tumours (four male, five female, 
median age 31.5 years, range 22-50 years) were identified from the St Mark’s 
Hospital Polyposis Registry and recruited prospectively.  All patients had 
undergone prophylactic colectomy. Patient demographics are summarised in 
Table 4.1. 
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Patient 
 
Age at DT 
diagnosis 
 
Gender 
 
APC mutation 
(codon) 
 
Surgery for 
FAP 
 
Current 
treatment 
 
1 
 
26 
 
F 
 
1392 
 
IRA 
 
Sulindac 
Toremifene 
 
2 
 
43 
 
M 
 
1465 
 
RPC 
 
- 
 
3 
 
50 
 
M 
 
1551 
 
RPC 
 
Chemotherapy 
 
4 
 
22 
 
M 
 
1556 
 
IRA 
 
Celecoxib 
 
5 
 
34 
 
M 
 
1551 
 
RPC 
 
- 
 
6 
 
24 
 
F 
 
1509 
 
RPC 
 
Observation 
 
7 
 
32 
 
F 
 
1182 
 
IRA 
 
Sulindac 
Toremifene 
 
8 
 
24 
 
F 
 
213 
 
IRA 
 
Sulindac 
Raloxifene 
 
9 
 
31 
 
F 
 
1444 
 
IRA 
 
Sulindac 
 
Table 4.1 - Patient demographics 
 
The inclusion criteria were the presence of a desmoid tumour; the exclusion 
criteria were standard exclusion criteria for MRI including presence of 
metalwork or pacemaker, inability to lie flat due to desmoid disease and 
claustrophobia.  
 
4.4.2 Regulatory approvals 
 
Regional ethics committee approval (Harrow Research and Ethics Committee 
Ref number: 07/H0719/100) was obtained for this study. Informed consent 
was obtained from all enrolled patients.  
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4.4.3 Image acquisition  
 
MRI was performed at 1.5-Tesla (Siemens Avanto, Siemens Healthcare, 
Erlangen, Germany) using a multi-coil multi-channel system. Patients 
underwent respiratory gated 3D T1-weighted, T2-weighted and STIR 
sequences encompassing the abdomen and pelvis in axial, coronal and 
sagittal planes (for MRI acquisition parameters refer to Table 3.2) prior to DTI. 
 
DTI encompassing the desmoid tumour, or the largest tumour if multiple 
tumours were present, in the axial plane with a 12cm z-axis coverage was 
performed using the following parameters: free breathing single shot echo 
planar sequence with parallel acquisition, parallel imaging factor 2; TR 
3000ms, TE 90ms, FOV 260mm, matrix 99x128, NEX 3, section 
thickness/coverage 5mm/120mm, b values: 0 and 800 s/mm2; 20 diffusion 
gradient orientations; pixel bandwidth 1600Hz; acquisition time 3 minutes 26 
seconds. 
 
4.4.4 Image analysis 
 
Images were viewed on a standard workstation (Leonardo, Siemens 
Healthcare, Erlangen, Germany) by two radiologists (with a specialist interest 
in gastrointestinal and oncological imaging) in consensus. The morphological 
sequences were viewed as a single contiguous volume of the abdomen and 
pelvis using the 3D taskcard. The site (IA, AW and EA), size, and T2 signal 
characteristics (signal intensity relative to muscle (hypo, iso or 
hyperintensity); and pattern of signal intensity (homogeneous, 
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heterogeneous)) were recorded for each desmoid tumour encompassed by the 
DTI sequence.           
                     
The diffusion tensor images were analyzed using commercial tensor software 
(Neuro3D, Siemens Healthcare), which automatically generated and 
displayed the following pixel maps: b0, fractional anisotropy (FA), relative 
anisotropy (RA) and diffusivity (apparent diffusion coefficient; ADC). FA and 
RA parametric maps provided complementary information. FA measures the 
fraction of diffusivity that can be ascribed to anisotropic diffusion (i.e., 
directionality; values range from 0 to 1, where 1 = highly directional) while 
RA represents the ratio of the anisotropic part to its isotropic part, or a 
normalized standard deviation (values range from 0 to √2). 
 
Pixel interpolation and a 40% threshold for display of each parameter map 
were employed. Regions of interest (ROI) were delineated around the tumour 
boundary on the b0 images, which had been previously registered and fused 
to corresponding T2-weighted images. These were replicated automatically 
by the software for the corresponding displayed FA, RA and ADC maps (Fig. 
4.1).  
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A       B 
      
C      D 
Fig 4.1 – Figure demonstrating T2-weighted (A), and corresponding fractional anisotropy (B), 
relative anisotropy (C) and apparent diffusion coefficient (D) maps of an extra-abdominal 
desmoid tumour 
 
The parameter values from all axial images inclusive of tumour were 
averaged to provide an overall tumour parameter value. The directionality of 
anisotropy was colour coded on the parameter maps as follows:  antero-
posterior (green), medio-lateral (red) and cranio-caudal (blue). The pattern of 
directionality was recorded for each desmoid tumour as follows: 
heterogeneous or homogeneous.  
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For the control muscle (erector spinae or gluteus maximus), a circular region 
of interest (112mm2) was placed centrally within the muscle, and the mean 
value for each parameter FA, RA, and ADC (x10-3), were recorded.  
 
4.4.5 Clinical treatment and follow up 
 
Clinical treatment in summarised in Table 4.1. Patients were followed up as 
per standard clinical practice with clinical assessment six monthly post 
ileorectal anastomosis (including flexible sigmoidoscopy) or one yearly post 
restorative proctocolectomy (including pouchoscopy). Imaging was repeated 
one year following initial imaging assessment.  
 
4.4.6 Statistical analysis 
 
Following testing for data normality, median values and range were 
calculated for the FA, RA and ADC values for all desmoid tumours and 
control muscles, and were compared using Mann-Whitney U test. FA, RA and 
ADC values were also compared for each site (IA, AW or EA) and for 
different T2 signal tumours (hypo, iso or hyperintense) using ANOVA and 
for different T2 pattern tumours (homogenous, heterogeneous) using Mann-
Whitney U test. A p-value less than 0.05 was considered statistically 
significant.  
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4.5 Results 
 
Fifteen desmoid tumours were evaluated: six IA, six AW and three EA, 
ranging in size from 1.6cm to 22.9 cm. The tumour characteristics (site, size, 
signal characteristics and pattern) on morphological and DTI sequences are 
summarised in Table 4.2. 
 
Morphology 
 
 
T2 characteristics 
 
DTI Signal pattern 
 
Size (cm) 
 
 
Baseline 
 
1 year post 
 
Tumour 
 
Site 
 
SI 
 
Baseline 
 
 
1 
year 
post 
 
Signal 
Intensity 
 
Pattern 
 
Signal 
Intensity 
 
Pattern 
 
Baseline 
 
1 year 
post 
 
1 
 
IA 
 
Infiltrative 
 
6.8 
 
5.5 
 
Hypo 
 
Homo 
 
Iso 
 
Homo 
 
No 
signal 
 
No signal 
 
2 
 
IA 
 
Mixed 
 
11.7 
 
10.5 
 
Iso 
 
Hetero 
 
Iso 
 
Homo 
 
Hetero 
 
No signal 
 
3 
 
AW 
 
Solid 
 
9.5 
 
6.9 
 
Hyper 
 
Hetero 
 
Hyper 
 
Hetero 
 
Hetero 
 
Hetero 
 
4 
 
EA 
 
Solid 
 
10.4 
 
7.4 
 
Hypo 
 
Homo 
 
Hypo 
 
Homo 
 
No 
signal 
 
No signal 
 
5 
 
EA 
 
Solid 
 
23.0 
 
22.9 
 
Hyper 
 
Hetero 
 
Hyper 
 
Hetero 
 
Hetero 
 
Hetero 
 
6 
 
EA 
 
Solid 
 
1.9 
 
3.1 
 
Hyper 
 
Hetero 
 
Hyper 
 
Hetero 
 
Homo 
 
Homo 
 
7 
 
AW 
 
Solid 
 
2.1 
 
1.6 
 
Hyper 
 
Homo 
 
Hyper 
 
Hetero 
 
Homo 
 
Homo 
 
8 
 
IA 
 
Infiltrative 
 
9.0 
 
8.2 
 
Iso 
 
Homo 
 
Iso 
 
Homo 
 
No 
signal 
 
No signal 
 
9 
 
AW 
 
Solid 
 
11.0 
 
10.1 
 
Hyper 
 
Hetero 
 
Iso 
 
Hetero 
 
Hetero 
 
Hetero 
 
10 
 
IA 
 
Mixed 
 
16.9 
 
6.2 
 
Hyper 
 
Hetero 
 
Hyper 
 
Hetero 
 
Homo 
 
Homo 
 
11 
 
AW 
 
Solid 
 
3.4 
 
3.7 
 
Hyper 
 
Hetero 
 
Hyper 
 
Hetero 
 
Homo 
 
Hetero 
 
12 
 
IA 
 
Mixed 
 
11.6 
 
- 
 
Hypo 
 
Hetero 
 
- 
 
- 
 
Hetero 
 
- 
 
13 
 
AW 
 
Solid 
 
22.7 
 
- 
 
Hyper 
 
Hetero 
 
- 
 
- 
 
Hetero 
 
- 
 
14 
 
IA 
 
Infiltrative 
 
11 
 
8.7 
 
Hypo 
 
Homo 
 
Hypo 
 
Homo 
 
Hetero 
 
No signal 
 
15 
 
AW 
 
Solid 
 
2.9 
 
1.3 
 
Hyper 
 
Homo 
 
Hyper 
 
Homo 
 
Homo 
 
Homo 
 
Table 4.2 - Summary of the characteristics of the individual desmoid tumours in successive 
patients 
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DTI was successful in 12 of 15 desmoid tumours on the baseline study. 
Quantification was not possible in two IA (mesenteric) and one EA desmoid 
tumours, which were of low signal on T1 and T2 sequences, due to dense 
fibrosis (Fig.4.2). 
 
    
A               B 
 
C 
 
At baseline median (range) of RA, FA and ADC were 0.23 (0.17 to 0.26), 0.27 
(0.21 to 0.31) and 1.65 (1.39 to 1.91) X10-3 mm2s-1 for desmoids. These were 
Fig 4.2 - T1 - weighted (A), T2 - weighted (B) 
and ADC (C) images of a patient with 
multiple desmoid tumours:  No diffusion 
signal was obtained for this EAD (arrow) on 
due to the extent of fibrosis 	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significantly different from control muscle: 0.27 (0.23 to 0.40), 0.32 (0.28 to 
0.46), and 1.45 (0.92 to 1.63) X10-3 mm2s-1  (p=0.0001, p=0.0001, p=0.0016 
respectively). There was no statistically significant difference in RA, FA or 
ADC between tumour sites (IA, AW or EA), or tumours of different signal 
intensity (hyper/iso/hypointense on T2-weighted sequences) and signal 
intensity patterns (homogeneous/heterogeneous) (Table 4.3). 
 
 
Tumour site 
 
 
T2 signal intensity 
 
Pattern 
 
Parameter 
 
IA 
 
AW 
 
EA 
 
P 
value 
 
Hyper 
 
Iso 
 
Hypo 
 
P 
value 
 
Homo 
 
Hetero 
 
P 
value 
 
FA 
 
0.254 
 
0.270 
 
0.253 
 
0.65 
 
0.264 
 
0.268 
 
0.268 
 
0.97 
 
0.275 
 
0.245 
 
0.77 
 
RA 
 
0.212 
 
0.228 
 
0.235 
 
0.65 
 
0.222 
 
0.226 
 
0.226 
 
0.98 
 
0.231 
 
0.208 
 
0.92 
 
ADC 
 
1.73 
 
1.62 
 
1.74 
 
0.53 
 
1.67 
 
1.57 
 
1.72 
 
0.77 
 
1.68 
 
1.63 
 
0.77 
 
Table 4.3 - Comparison of fractional anisotropy (FA), relative anisotropy (RA) and apparent 
diffusion coefficient (ADC) by desmoid tumour site, T2 signal intensity, and pattern 
 
At follow up one year later, two patients had died (one from desmoid related 
disease; one from pulmonary embolus); leaving 13/15 tumours for analysis. 
Of these DTI was possible in only 8/13 tumours. The majority of tumours 
decreased in size (median: 10.4 to 6.2cm; p=0.04); tumour increased in size in 
only one patient (1.6 to 3.1cm; +61%). Median (range) of desmoid tumour RA, 
FA and ADC were 0.24 (0.19 to 0.32), 0.28 (0.23 to 0.37) and 1.85 (1.48 to 2.06) 
x10-3 mm2s-1 respectively; this was not significantly different from baseline 
(p=0.77, 0.71 and 0.34 respectively). 
 
	   90	  
4.6 Discussion 
 
This study demonstrated that desmoid tumours show anisotropy: FA, RA and 
ADC differed from normal skeletal muscle, but did not vary significantly 
between sites, T2 signal intensity or pattern. In general FA and RA were lower 
than normal muscle (Kermarrec et al, 2010) indicating a less directional 
pattern than muscle fibres. This is not surprising given macroscopic and 
microscopic appearances at pathological evaluation. The lack of significant 
difference in values between tumour sites may reflect the small number of 
tumours in this exploratory study, however, there was a trend for AW and 
EA tumors to have higher FA and RA than IA tumours.  
 
High T2 signal intensity has been suggested as a marker of disease activity 
(Healy et al, 1997): FA, RA and ADC values did not differ for hypo, iso or 
hyperintense tumours indicating this reflects a different aspect of tumour 
biology which may complement other MRI parameters. The majority of 
tumours showed shrinkage at one year. ADC increased indicating a reduction 
in cellularity mirrored by a decrease in T2 signal intensity in some lesions, 
though this was not statistically significant. FA and RA were not significantly 
different. These preliminary data support the hypothesis that assessment of 
water diffusion may potentially provide additional clinically relevant 
information, but requires further study.  
 
ADC values in our study were comparable with a recently published 
diffusion weighted (DW) MRI study encompassing 8 sporadic tumours, 
which showed that sporadic desmoids had higher ADC values compared 
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with other soft tissue tumours (1.36 versus 0.88 X10-3 mm2s-1) indicating these 
are less cellular (Oka et al, 2011). 
 
4.7 Summary 
 
There are limitations to this study. Firstly the assessment of desmoid tumours 
DWI was not feasible in three out of fifteen tumours initially, increasing to 
five tumours at one year follow up due to the dense fibrosis. Secondly patient 
numbers were small, and only one patient’s tumour showed interval growth; 
but it should be recognized that this is a very rare condition.  Thirdly there 
was a lack of pathological correlation, however, surgery is only undertaken 
following careful consideration in patients with desmoid tumours in FAP and 
none of these patients underwent surgery subsequent to MRI.  
 
In summary, this study has shown that DTI is feasible for the assessment of 
desmoid tumours in FAP.  Desmoid tumours show anisotropy, but this is less 
directional than normal muscle. DTI parameters may reflect the tumour 
microstructure, however, its clinical role remains indeterminate, requiring 
further evaluation. 
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Chapter 5 
 
 
Role of Dynamic Contrast Enhanced Magnetic 
Resonance Imaging (DCE-MRI) and Fluorine-18 
Flurodeoxyglucose Positron Emission Tomography (18F-
FDG PET) in predicting behaviour of desmoid tumours 
in familial adenomatous polyposis 
 
5.1 Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-
MRI) 
 
Conventional contrast-enhanced MRI displays a single snapshot of tumour 
enhancement after contrast administration. While such image can provide 
useful anatomical information, it lacks functional information. Dynamic 
contrast-enhanced magnetic resonance imaging (DCE-MRI), on the other 
hand, relies on fast MRI sequences obtained before, during and after the rapid 
intravenous administration of a gadolinium based contrast agent. This MRI 
technique is almost analogous to a movie and enables the depiction of 
physiologic alterations as well as morphologic changes in the tissue (Türkbey 
et al, 2010). DCE-MRI images can be quantified to provide information on 
tumour perfusion, vessel permeability and volume of extracellular extra 
vascular space. These quantifications serve as a non-invasive biomarker for 
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tumour angiogenesis, which is a key step in the pathophysiology of tumour 
growth and metastatic spread (Padhani et al, 2001).  
 
DCE-MRI has been increasingly used for the initial diagnosis and staging of 
many tumours. Moreover, it has been used as a biomarker for monitoring 
response to conventional chemotherapy, antiangiogenic therapy or 
radiotherapy for various cancer types such as colon, prostate, breast and 
gynecologic malignancies (Türkbey et al, 2010)  
 
5.2 Fluorine-18 Flurodeoxyglucose Positron Emission Tomography (18F-
FDG PET) 
 
Positron emission tomography (PET) is a molecular imaging technique used 
to detect abnormal behaviour of tissues. Fluorine-18-deoxyglucose (FDG) is a 
radionuclide labeled glucose analogue commonly used in clinical practice for 
molecular probing. This is based on the fact that abnormal tissue such as 
tumour exhibits markedly increased rates of glucose metabolism. 
 
After administration, FDG is actively transported into cells, mediated by a 
group of structurally related glucose transport proteins. Once intracellular, 
FDG (like glucose) is phosphorylated by hexokinase as the first step in the 
glycolytic metabolism pathway. While normal glucose continues along the 
glycolytic pathway for energy production, FDG cannot enter the glycolytic 
pathway and becomes effectively trapped intracellularly as FDG-6-phosphate. 
Most tumour cells are highly metabolically active with high mitotic rates and 
display increased numbers of glucose transporters as well as higher levels of 
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hexokinase. These mechanisms allow tumour cells to take up and retain 
higher levels of FDG when compared to normal tissues. 
 
PET/CT fuses functional information from PET and anatomic information 
from CT scan simultaneously and allows for these to be viewed and 
interpreted together. The multidetector CT apparatus and the PET detectors 
are mounted in the same gantry, one immediately behind the other, and scans 
are performed with the patient lying in the same position on the imaging 
table. For interpretation, the PET data is actually superimposed upon the CT 
data resulting in improved anatomic localisation of normal and abnormal 
FDG activity. 
 
18F-FDG PET CT has been widely used in clinical setting to stage, monitor 
response to chemotherapy and detect metastasis and recurrence in wide 
variety of cancer (Facey et al, 2007). It has also been used as a prognostic 
biomarker. High uptake of 18F-FDG has also been associated with tumour 
angiogenesis and found to be predictive of aggressive features of cancer cells 
in early breast cancer patients (Ueda et al, 2008; Groves et al, 2011), and other 
cancers including lung and oesophagus (Reske et al, 2001). 
 
5.3 DCE-MRI and FDG PET in desmoid tumour 
 
The use of DCE-MRI in the characterisation and assessment of behaviour of 
desmoid tumour has not been reported before. There are limited reports in 
the literature of use of PET CT to assess desmoid tumour. In a small series of 
patients, Basu et al have suggested a change in FDG uptake by desmoids as a 
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marker of response to chemotherapy and discussed its potential role in 
predicting their aggressive behaviour (Basu et al, 2007). Previous 
clinicopathological studies in desmoid tumour have reported a correlation of 
increased vascularity with aggressive behaviour of desmoid and tendency to 
recurrence (Kouho et al, 1997; Yokohama et al, 1989). From these studies one 
can hypothesize that aggressive desmoids are potentially more vascular and 
metabolically more active. Therefore combination of DCE-MRI, which 
provides functional (vascularity) information, and FDG PET/CT, which 
provided metabolic information, may be useful in providing complementary 
information on tumour behaviour. 
 
5.4      Aim of the study 
 
The aim of this study was to investigate whether vascular (DCE-MRI) and 
metabolic imaging (FDG PET CT) can predict the aggressive desmoid 
tumours in FAP patients, allowing these to be identified and treated early. 
 
5.5       Materials and method 
 
5.5.1 Patient selection 
 
FAP patients with confirmed desmoid tumours based on previous 
radiological and clinical evidence were identified from the St Mark's Hospital 
Polyposis Registry and prospectively recruited. Inclusion criteria included 
FAP patients with known desmoids and exclusion criteria included 
claustrophobia and presence of metal implant for MRI and known diabetes 
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for PET. All patients underwent MRI, including DCE-MRI sequences, and 
FDG PET CT imaging of the abdomen and pelvis with scans performed on the 
same day. A conventional follow up MRI scan was performed after one year 
to determine tumour growth. 
 
5.5.2 Regulatory approvals 
 
Regional ethics committee approval (Harrow Research and Ethics Committee 
reference number: 07/H0719/100) and informed consent from enrolled 
patients was obtained for this study.  
 
5.5.3 MRI and DCE-MRI examinations  
 
MRI was performed using a 1.5-Tesla MR scanner (Siemens Avanto, Siemens 
Medical Solutions, Erlangen, Germany) and a multichannel surface coil. T1, 
T2-weighted, and short tau inversion recovery (STIR) sequences of the 
abdomen and pelvis in the axial, coronal and sagittal planes were 
supplemented by dynamic contrast enhanced MRI. The acquisition 
parameters are listed in Table 5.1. 
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TR (ms) 
 
TE (ms) 
 
TI (ms) 
 
FA (0) 
 
Slice thickness 
(mm) 
 
FOV (mm) 
 
Sequence 
    
 
NEX 
  
 
Matrix 
 
T1 axial bh 
Abdo and 
pelvis 
 
138 
 
4.76 
 
- 
 
70 
 
1 
 
8 
 
300*263 
 
256*179 
 
T2 axial bh 
Abdo and 
Pelvis 
 
97 
 
2180 
 
- 
 
150 
 
1 
 
5 
 
300*300 
 
512*512 
 
STIR axial 
 
3800 
 
93 
 
150 
 
160 
 
1 
 
5 
 
300*300 
 
256*256 
 
Proton Density 
axial for DCE 7.38 4.76 - 2 6 5 300*300 512*512 
 
 
T1W DCE 7.38 4.76 - 18 
1 *40 
repeats 5 300*300 512*512 
 
Table 5.1 - MRI diagnostic acquisition parameters 
 
 
Respiratory gating was used to reduce movement artifacts caused by 
breathing, and 10mg of intravenous hyoscine-N-butylbromide (Buscopan; 
Boehringer Ingelheim, Bracknell, Berkshire, England) was administered to 
reduce peristalsis.  
 
The DCE-MRI studies were performed following 0.1mlkg-1 gadolinium-based 
intravenous contrast injection (Magnevist™, Bayer, Burgess Hill, West Sussex, 
UK), using a 3D VIBE sequence and the following parameters:  TR  7.38ms, TE  
4.76ms, FOV 300mm*300mm, Matrix 512*512, Flip angle 200 (proton density) 
and 1800 (dynamic scan), Slice thickness 5mm; dynamic scan interval 11.9s: 
total acquisitions 40. 
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5.5.4 Whole body 18F-FDG PET/CT examinations 
 
Patients were injected with 4.5MBq (18F) FDG per kilogram body weight 
(maximum of 370 MBq) after a fasting period of at least six hours. Patients 
stayed in a quiet and darkened room for 60-90 minutes. (18F) FDG imaging 
was performed on an integrated PET-CT system (GE Discovery VCT, GE 
Healthcare, Amersham, UK). Following CT for attenuation correction (140kV, 
80mA, 0.8s/rotation, Pitch 1.5, Slice thickness 3.75mm), the PET emission 
scans covering the same anatomical area were carried out in 2D mode, 
consisting of an emission scan of 8 minutes/bed position. Transaxial emission 
images of 5.47×5.47×3.27mm (in plane matrix size 128×128) were 
reconstructed using OSEM with two iterations and 28 subsets. The axial field 
of view was 148.75 mm.  
 
5.5.5 Image analysis 
 
Images were transferred and viewed on a standard workstation (Leonardo, 
Siemens Healthcare, Erlangen, Germany) by two radiologists (with a 
specialist interest in gastrointestinal imaging) in consensus. The 
morphological sequences were viewed as a single contiguous volume of the 
abdomen and pelvis using the 3D taskcard to facilitate identification of all 
desmoid tumours in the abdomen and pelvis. The site, size and signal 
characteristics of the tumour were recorded. 
 
The DCE-MRI images were transferred to a workstation, and assessed using 
proprietary software (Magnetic	   Resonance	   Imaging	   Workbench, Institute of 
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Cancer Research). Following motion correction and image registration, the 
DCE-MRI data were quantified to give T1 values, and hence Gadolinium 
concentration.  An extended Kety model (Tofts) (Tofts PS, 1997) with a 
modified Fritz-Hansen assumed AIF (Arterial Input Function) (Walker-
Samuel S et al, 2006) was used to describe the uptake of contrast within the 
region of interest:  
 
 
 
where Ct = tissue concentration of contrast agent, Ktrans = transfer constant,  
ve= extravascular extracellular volume and the derived rate constant kep, = 
Ktrans/ve. 
 
 Ktrans (transfer constant), ve (extravascular extracellular space, EES), kep (rate 
constant) and IAUGC60 (integrated area under the gadolinium-time curve at 
60s) were derived by region of interest analysis.  Ktrans   is a parameter related 
to vessel permeability and tissue blood flow, Ve is an estimate of the 
extravascular extracelllular space, Kep represents transfer constant from EES to 
plasma. The DCE-MRI parameters of each slice were recorded and averaged 
to obtain whole tumour DCE-MRI estimates. 
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FDG-PET/CT images were reviewed by a radiologist experienced in desmoid 
imaging and a nuclear medicine specialist in consensus. For each desmoid 
tumour identified on PET CT, the maximum Standardarised Uptake Value 
(SUVmax) was derived for the volume-of-interest (VOI) defined for the tumour.  
 
Fig 5.1 - DCE-MRI image of an abdominal wall desmoid with region of interest (ROI) 
drawn around the tumour 	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Fig 5.2 - 18F FDG PET CT images of desmoid tumour. The abdominal wall/ pelvic desmoid 
tumour in this image had SUVmax value of 3.9 (asterisk and arrow) 
 
5.5.6 Outcomes of interest 
 
For each modality the number of desmoids was documented. The size of 
desmoid was obtained in MRI by automated region of interest analysis and 
the area was recorded in cm2. All desmoid lesions were classified by site into 
IAD, AWD or EAD. IAD were all mesenteric desmoids; AWD included 
desmoids located in anterior and posterior abdominal wall muscles; EAD 
incorporated desmoids at other sites. Desmoids were also classified according 
to change in size between first and follow up MRI scan. Increase in size by 
10% or more was recorded as growth, decrease in size by 10% or more was 
recorded as regression and rest were classified as stable desmoids. 
 
5.5.7 Statistical analysis 
 
Statistical analysis was conducted using STATA™ SE 10.1 for Macintosh 
(STATA Corp, Texas, USA). DCE-MRI parameters ( Ktrans, Ve, Kep, IAUGC60 ) 
were described as mean and standard deviation. Vascular Parameters (Ktrans, 
Ve, Kep, IUC) and SUVmax and the ratio of Ktrans/ SUVmax were compared for 
each site (IAD, AWD and EAD) and for size change (increased, decreased or 
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stable) using one-way analysis of variance (ANOVA). SUVmax was correlated 
with vascular parameters using Spearmann Rank correlation. A p-value less 
than 0.05 was considered statistically significant.  
 
5.6 Results  
 
Nine patients with FAP and desmoid disease underwent MRI and PET CT on 
the same day. Please refer to Table 4.1 for the demographic details of the 
included patients. 
 
Twenty-three desmoids (9 IAD, 10 AWD and four EAD) were identified on 
MRI. PET-CT was quantifiable in 21 desmoids. Due to failure to cannulate one 
patient (patient 9, Table 4.1), DCE MRI was possible in only 8 patients. DCE 
MRI was quantifiable in 13/19 tumours  (7 AW, four IA and two EA) in the 
remaining 8 patients. Quantification was not possible in 6 tumours (four IA 
and two AW) due to extensive fibrosis and poor vascularity. Two patients 
died between the studies leaving only 11 tumours on follow up MRI one year 
later for analysis of combined DCE-MRI and PET-CT parameters and 
subsequent growth. Table 5.2 summarises signal characteristics, DCE-MRI 
parameters, size change and SUVmax of these tumours. 
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Table 5.2 - Description of the tumours 
  
 
The mean (sd) value of DCE Kinetic parameters, Ktrans, Ve, Kep, IAUGC60 was 
0.175 (0.097), 0.507 (0.152), 0.366 (0.186), 12.23 (6.05). The mean (sd) SUVmax 
was 4.54 (1.78). SUVmax was significantly negatively correlated with Kep but 
not with other vascular parameters (Ktrans, Ve, IAUGC60) (Table 4.4). Desmoid 
of size >30 cm2 on the initial MRI had significantly higher SUVmax/ Ktrans ratio 
compared to size <30 cm2 (p=0.03) (Table 5.3). 
 
 
 
Patient	   Site	   T2-­
Signal	  
Ktrans	   Ve	   Kep	   IAUGC60	   Initial	  
MR	  
Size	  
(cm2)	  
Follow	  
up	  MR	  
size	  
(cm2)	  
	  SUVmax	   	  	  SUVmax/Ktrans	  
1	   IA	   low	   0.231	   55.3	   0.448	   13.40	   27.6	   16.3	   	  	  	  	  4.2	   	  	  	  	  	  	  	  	  	  	  18.18	  	  2	   AW	   mixed	   0.080	   59.4	   0.137	   9.85	   191.2	   -­‐	   	  	  	  	  8.3	   	  	  	  	  	  	  	  	  	  	  103.75	  	  3	   EA	   low	   0.038	   29.3	   0.171	   0.95	   145.7	   181.5	   	  	  	  	  8.1	   	  	  	  	  	  	  	  	  	  	  213.15	  	  3	   AW	   mixed	   0.143	   64.3	   0.234	   16.88	   32.2	   24.2	   	  	  	  	  4.1	   	  	  	  	  	  	  	  	  	  	  28.67	  	  3	   EA	   low	   0.053	   15.0	   0.362	   2.97	   30.4	   26.8	   	  	  	  	  3.0	   	  	  	  	  	  	  	  	  	  	  56.60	  	  4	   AW	   mixed	   0.195	   67.9	   0.295	   17.17	   47.3	   24.5	   	  	  	  	  4.3	   	  	  	  	  	  	  	  	  	  	  22.05	  	  4	   AW	   low	   0.055	   17.7	   0.298	   3.38	   3.17	   2.5	   	  	  	  	  3.3	   	  	  	  	  	  	  	  	  	  	  60	  	  5	   IA	   low	   0.174	   60.0	   0.312	   9.82	   70.7	   -­‐	   	  	  	  	  4.2	   	  	  	  	  	  	  	  	  	  	  24.13	  	  6	   AW	   mixed	   0.095	   47.4	   0.214	   6.44	   89.5	   25.3	   	  	  	  	  5.1	   	  	  	  	  	  	  	  	  	  53.68	  	  6	   AW	   mixed	   0.378	   55.8	   0.671	   21.34	   2.5	   5.5	   	  	  	  	  3.9	   	  	  	  	  	  	  	  	  10.31	  	  7	   IA	   low	   0.238	   38.2	   0.649	   12.61	   18.1	   18.3	   	  	  	  	  2.8	   	  	  	  	  	  	  	  	  11.76	  	  8	   IA	   low	   0.234	   39.6	   0.612	   11.97	   25.3	   34.8	   	  	  	  	  5.3	   	  	  	  	  	  	  	  	  22.64	  	  8	   AW	   mixed	   0.280	   60.2	   0.488	   18.34	   2.1	   1.5	   	  	  	  	  2.9	   	  	  	  	  	  	  	  	  10.35	  	  
	   104	  
 
Variable 1 
 
 
Variable 2 
 
Spearman ρ  
 
P value 
 
SUVmax 
 
 
 
Ktrans 
 
-0.47 
 
0.09 
 
SUV max 
 
 
ve 
 
-0.11 
 
0.72 
 
SUV max 
 
 
kep 
 
-0.56 
 
0.04 
 
SUV max 
 
 
IAUGC60 
 
-0.47 
 
0.10 
 
Table 5.3 - Correlation analysis of SUVmax and DCE-MRI parameters 
 
 
Five tumours decreased in size, three increased in size and three remained 
stable after a year. There was no significant difference in the SUVmax or DCE 
parameters (Ktrans, Ve, Kep, IAUGC60) between the tumours that grew or shrank 
or between the tumour sites. However ratio of SUVmax/Ktrans was significantly 
different for size change and between the sites of tumour (Table 5.4).  
 
 
Tumour Size 
 
Tumour Site 
 
Parameters 
 
Increased 
 
Decreased 
 
Stable 
 
P 
value 
 
IA 
 
AW 
 
EA 
 
P 
value 
 
Ktrans 
 
0.21 
 
0.17 
 
0.17 
 
0.32 
 
0.21 
 
0.17 
 
0.09 
 
0.13 
 
ve 
 
0.41 
 
0.49 
 
0.56 
 
0.83 
 
0.48 
 
0.53 
 
0.46 
 
0.61 
 
kep 
 
0.49 
 
0.34 
 
0.36 
 
0.36 
 
0.50 
 
0.33 
 
0.20 
 
0.46 
 
IAUGC60 
 
11.63 
 
11.74 
 
15.24 
 
0.31 
 
11.95 
 
13.34 
 
8.91 
 
0.06 
 
SUVmax 
 
4.93 
 
3.96 
 
4.13 
 
0.16 
 
4.12 
 
4.55 
 
5.55 
 
0.30 
 
SUVmax/Ktrans 
 
78.78 
 
32.02 
 
24.08 
 
0.001 
 
19.18 
 
41.45 
 
117.62 
 
0.001 
 
 
Table 5.4 - Comparision of DCE parameters and SUVmax by tumour growth and site 
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All 21 tumours were quantifiable on PET CT (Mean SUVmax 3.91 (SD 1.71)); no 
correlation between SUVmax and change in size was noted in the whole cohort. 
 
5.7 Discussion 
 
This study found that desmoid tumours are generally hypovascular (low 
Ktrans), with a large volume of distribution (high Ve) and poorly glucose avid 
(low SUVmax). FDG uptake in desmoid tumour was heterogeneous, consistent 
with the findings by Basu et al.  However unlike their suggestion, FDG 
uptake did not predict aggressive tumours: desmoid tumour glucose uptake 
did not differ significantly between the tumours that grew or shrank. 
Furthermore the study by Basu et al included only one FAP associated 
desmoid. This is clinically relevant as FAP desmoids are genetically and 
biologically different from sporadic desmoids.  
 
In this study the larger tumours had a higher metabolic-vascular ratio than 
smaller tumours – indicating a greater mismatch between glucose metabolism 
and vascularisation. This is consistent with data from cancer e.g. lung (Miles 
et al, 2006). SUVmax correlated negatively with Kep indicating metabolic activity 
was higher in tumours with greater contrast agent retention, and slower 
washout. There was also a significant difference in the metabolic vascular 
ratio between the tumour sites; the clinical significance of this remains 
uncertain and needs exploring with further studies. 
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5.8 Limitations of this study 
 
There are limitations to this study. Firstly the number of patients studied was 
small, however desmoid is an uncommon manifestation of a rare disease. 
Two patients died before follow-up imaging, one due to desmoid (Patient 2 
Table 4.1). This tumour was the most avid for glucose uptake (SUVmax 8.3) but 
had low vascularity (Low ktrans) and high volume of distribution (high Ve). 
While only 11 of 23 tumours were imaged successfully by both DCE-MRI and 
PET-CT, and were assessed for growth after one year, this is the first study 
and largest such series evaluating the potential of non-invasive imaging in 
characterising the behaviour of desmoid tumours in FAP patients. 
 
Secondly, eight out of these eleven tumours either remained stable or 
decreased in size. Only three showed interval growth. As only 10% of FAP 
desmoids show aggressive behaviour, it is not surprising that this small 
cohort of patients did not include many of aggressive type.  
 
Thirdly, patients were on different treatments during the study and there is a 
possibility that this might have reduced growth in some of the tumours. 
However some tumours remained stable and others decreased or increased in 
size during the study period in the same patient implying different biology 
and response of individual tumour. Moreover it is difficult to comment on the 
effect of the treatment as there is no good trial evidence of efficacy.  
 
As an exploratory study the primary aim was to study role of these imaging 
techniques as a predictor for aggressive behaviour in desmoids. Larger 
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studies in future involving patients on medication or without may help clarify 
this issue further. 
 
5.9  Summary 
 
Desmoids are a major cause of morbidity and mortality in post-colectomy 
FAP patients and a non-invasive test, which could potentially identify rapidly 
growing tumours early, may benefit these patients by allowing a more 
aggressive approach to treatment early.  
 
This study has not conclusively shown 18F-FDG-PET or DCE-MRI to be of use 
in this context, probably because there were insufficient actively growing 
desmoids in this small cohort. However, taken together with previous studies 
showing high 18F-FDG avidity in some desmoids, this study has shown that a 
spectrum exists on this imaging modality, which warrants further 
exploration. 
 
This study also highlights the difficulty of studying a rare and unpredictable 
tumour. In future international collaboration between centres specialising in 
these rare tumours and a trial involving large number of patients may help to 
further explore the use of modern imaging techniques in characterising 
desmoid tumour behaviour. 
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PART 3 – CLINICAL STUDY 
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Chapter 6 
 
 
A clinical review of familial adenomatous polyposis 
associated desmoid tumours presenting with air fluid 
level 
 
6.1 Background 
 
Seventy percent of FAP-related desmoids occur in the abdomen, primarily 
arising in the small bowel mesentery and abdominal wall (Clark et al, 1999). 
IAD are associated with significantly poorer survival in comparison to AWD 
(Phillips et al, 2007). A relatively common clinical situation in aggressive IAD 
is the development of a liquefied centre containing gas, accompanied by 
abdominal pain and sepsis. Some authors have described this as desmoid 
fistula; however, the term ‘fistula’ refers to an abnormal communication 
between two epithelial surfaces, so this terminology is not used in our unit. 
The term ‘air-fluid level (AFL)’ is preferred, and it encompasses a spectrum of 
pathology ranging from necrosis, abscess formation and direct 
communication with the bowel. There is no clear guidance in the literature on 
the management of this difficult problem. 
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6.2 Aims of this study 
 
The aims of the study were to understand the underlying mechanism of air-
fluid level development in IAD and review our experience in the 
management of these complications of IAD grouped together as 'IAD with 
air-fluid level', and to formulate a treatment algorithm. 
 
6.3 Methods 
 
6.3.1 Patient selection 
 
The St Mark’s Hospital Polyposis Registry database was searched for patients 
with a diagnosis of FAP, defined by either an identified APC mutation or the 
presence of over 100 colorectal adenomas with no evidence of MYH mutation. 
Only those patients diagnosed with IAD containing air-fluid level on 
abdominal contrast enhanced CT or MRI were included in this study. These 
investigations were reported by experienced gastrointestinal radiologists 
familiar with imaging for patients with FAP, and were reviewed in a 
multidisciplinary setting. Patients developing only extra-abdominal desmoids 
or IAD without air-fluid levels were excluded. 
 
6.3.2 Data collection 
 
For included patients data were collected on patient demographics, type of 
surgery performed for FAP (IRA or RPC), age at primary surgery, site of IAD 
and age at diagnosis of IAD with AFL. Patients were grouped by treatment 
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received into non-operative, percutaneous drainage and open surgery 
categories. 
 
6.3.2  Outcome of interest 
 
The prospectively maintained dataset was analysed, the outcome of interest 
being change of treatment strategy and their outcome in the management of 
this complicated condition. 
 
6.4 Results 
 
Two hundred and forty six patients with DT were identified from the St 
Mark’s Polyposis Registry database. Of these, a total of nine patients had an 
IAD with air-fluid level; seven were female. Table 6.1 outlines the 
demographics of the nine patients along with the type of primary surgery 
performed and the age of diagnosis of the IAD with air-fluid level and site of 
IAD.  
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Patient 
 
Gender 
 
Surgery for 
FAP  
 
Age at 
surgery 
(Yrs) 
 
Age at diagnosis of 
IAD with AFL (Yrs) 
 
Site of IAD 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
           8 
 
 
9 
 
F 
 
F 
 
F 
 
F 
 
F 
 
M 
 
F 
 
F 
 
 
M 
 
RPC 
 
IRA 
 
IRA 
 
TPC 
 
RPC 
 
RPC 
 
IRA 
 
IRA 
 
 
Nil 
 
33 
 
19 
 
20 
 
30 
 
18 
 
34 
 
21 
 
18 
 
 
Nil 
 
37 
 
22 
 
24 
 
31 
 
24 
 
41 
 
24 
 
20 
 
 
36 
 
SBM 
 
SBM 
 
SBM and pelvis 
 
SBM 
 
SBM and pelvis 
 
SBM 
 
SBM 
 
SBM and 
retroperitoneum 
 
SBM 
 
Table 6.1 - Patient & DT demographic data 
 
Patient 9 who presented with IAD with air-fluid level had attenuated 
phenotype of FAP and still had his colon in situ. In the remaining patients, the 
median time taken from primary surgery to DT development was 24 months 
(range 0 – 48 months) and the median time for progression to air-fluid level 
from desmoid diagnosis was 24 months (range 0 – 226 months). Figure 6.1 
displays a typical IAD containing an air-fluid level on CT. 
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Fig 6.1 – Typical example of IAD with AFL on CT 
 
In the nine patients, IAD diameter ranged from 10cm to over 20cm (Table 6.2). 
Possible communication from the IAD to the small bowel was reported on 
cross-sectional imaging in 8 patients; unusually there was communication to 
both the small bowel and the reproductive tract in an isolated case. This 
patient presented with discharge of enteric contents from the vagina.  
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Patients 
 
DT max 
diameter 
(cm) 
 
 
Communication 
 
Microbiology 
culture from 
DT 
 
Primary 
Procedure 
 
Secondary 
Procedure 
 
1 
 
>20 
 
Small bowel & 
Uterus 
 
Coliform 
 
Percutaneous 
drain 
 
Surgery 
 
2 
 
17 
 
Small bowel 
 
Coliform 
 
Percutaneous 
drain 
 
- 
 
3 
 
 
15 
 
Small bowel 
 
Coliform 
 
Surgery 
 
- 
 
4 
 
>20 
 
Small bowel 
 
E. Coli & VRE 
 
Percutaneous 
drain 
 
Surgery 
 
5 
 
11 
 
Small bowel 
 
Coliform 
 
Percutaneous 
drain 
 
- 
 
6 
 
 
12 
 
Small bowel 
 
Nil 
 
Non operative 
 
- 
 
7 
 
 
>20 
 
Small bowel 
 
Coliform 
 
Surgery 
 
- 
 
8 
 
 
10 
 
Nil 
 
Coliform 
 
Surgery 
 
- 
 
9 
 
 
>20 
 
 
Small bowel 
 
 
Nil 
 
 
Non operative 
 
 
- 
 
 
Table 6.2 - DT characteristics 
 
Two patients presented with fever and abdominal pain and were successfully 
treated with antibiotics alone. Intravenous antibiotics were administered in 
accordance with our local guidelines for intra-abdominal sepsis (Co-
amoxiclav 1.2g tds (or cefuroxime 1.5g tds if penicillin allergic) and 
metronidazole 500mg tds).  
 
Four patients, who presented with abdominal pain and sepsis, were initially 
treated with intravenous antibiotics but failed to improve and underwent 
percutaneous drainage of AFL. However, this treatment was successful in 
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only two. Of these, ultrasound guided percutaneous drainage sufficed in one 
but the other required a small surgical incision to insert a drain. This patient 
had a hard rim of desmoid visible on ultrasound scan, which could not be 
traversed with a standard percutaneous drain.  
 
The two patients who failed to settle after percutaneous drainage had 
multiloculated AFL on CT scan and developed progressive sepsis ultimately 
requiring surgery, which involved excision of desmoid with enterectomy in 
one and loop jejunostomy in the other. The latter patient has since 
successfully undergone multivisceral small bowel transplant.  
 
The remaining three patients presented with generalised peritonitis and 
underwent urgent laparotomy. One had necrotic IAD with AFL and required 
drainage only. One required drainage of desmoid with loop jejunostomy that 
was later reversed. One patient underwent excision of desmoid with loop 
jejunostomy but developed progressive disease and died while awaiting 
multivisceral small bowel transplant. The treatment of the nine patients and 
outcomes are summarised in table 6.3. 
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Most invasive 
intervention  
 
 
 
No of patients 
 
 
Morbidity 
 
 
30 day Mortality 
 
Antibiotics only 
 
 
2 
 
Nil 
 
Nil 
 
Percutaneous drainage  
 
 
2 
 
Nil 
 
Nil 
 
 
      Operative 
 
 
Excision ± Proximal 
defunctining 
 
Drainage ± Proximal 
defunctioning 
 
 
                   
                  5 
 
 
 
3 
 
 
2 
 
 
 
 
 
 
1 (EC Fistula) 
 
 
Nil 
 
 
 
 
 
 
1 
 
 
Nil 
  
Table 6.3 - Management & outcome of DT with air-fluid level 
 
Microbiology culture data from the IAD was available for seven of the nine 
patients and mainly grew coliform organisms.  Five of these seven patients 
underwent laparotomy, desmoid enteric fistula was found in four and one 
patient only had necrotic desmoid, without connection to bowel. 
 
Patient 1 developed an enterocutaneous fistula (ECF) through mesh placed to 
the reconstruct abdominal wall, following excision of desmoid of diameter 
greater than 20cm. This patient is currently awaiting further surgery for the 
ECF. The other patients had no significant morbidity.  
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6.5 Discussion 
 
The complication of an air-fluid level in FAP related IAD is a rare 
phenomenon – only nine patients in this series (4%), but this represents 
approximately half of the significant morbidity associated with these 
desmoids.  However this prevalence may be an overestimation as St Mark’s 
Hospital is the tertiary centre specialising in these tumours and receives 
referral from across the country. Three out of nine patients in this series were 
referred from other units specifically for management of DT.  
 
Apart from an isolated case report (Yu et al, 2009), the only publication 
focusing on this complication has been a case series of three patients. In that 
paper, Maldjian et al considered only percutaneous drainage of DT with 
abscess formation (Maldjian et al, 1995). To date, no studies have specifically 
addressed the management of DT communicating with the small bowel 
lumen, abscess formation or necrosis of DT, which has been termed DT with 
an air-fluid level in this study.  
 
The mechanism by which an AFL develops within a DT is unknown. The 
development of an AFL involves a combination of central necrosis and 
liquefaction, coupled with either infection or communication with gas in the 
gut lumen. Microbiological data from this series, showing mainly coliform 
and E.coli , supports the source of infection being the translocation or 
communication between the DT and the bowel lumen, probably due to 
localised bowel ischemia/perforation. In four of the five patients who 
underwent surgery, a direct communication with small bowel (desmoid 
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enteric fistula) was found. The fifth patient had only necrotic desmoid with 
no obvious communication with bowel. However the fluid culture from this 
patient also detected coliform organism, suggesting the translocation of gut 
organism as explanation for the culture finding.  
 
This series demonstrates a spectrum of management, ranging from 
conservative to highly interventional treatment ultimately leading to 
multivisceral transplantation. Church et al have described a classification 
system for IAD that may help with prospective management decisions. This 
system is based on DT size and resulting symptoms and described in table 6.4 
(Church et al, 2005; Church et al, 2008).  
 
 
Stage 
 
 
Description 
 
I 
 
Asymptomatic, <10cm maximum diatemeter, and not growing 
 
 
II 
 
Mildly symptomatic, <10cm maximum diameter, and not growing 
 
 
III 
 
Moderately symptomatic or bowel/ureteric obstruction, or 10 to 20cm, or slowly 
growing 
 
 
IV 
 
Severely symptomatic, or >20cm, or rapidly growing 
 
 
Table 6.4 - Desmoid tumour staging system (adapted from Church et al paper published in 
Diseases of colon and rectum, 2008 Jun; 51(6): 897-901) 
 
All of the IAD in patients in this series with air-fluid levels had stage III or IV 
disease. Of the three patients with stage III disease, two were successfully 
treated with percutaneous drainage and antibiotics and one was successfully 
treated with antibiotics alone. Out of six remaining patients with stage IV 
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IAD, one was successfully treated with antibiotics alone and the rest required 
surgery. The two patients with the largest IAD, both larger than 20cm in 
diameter, were considered for small bowel multi-visceral transplantation. 
One patient underwent a transplant, and the other died while awaiting it. 
From our series, size of DT alone could not predict the need for surgery as 
one of the patients managed by percutaneous drainage had an IAD 
measuring 17cm and other managed with antibiotics alone had IAD of 
diameter more than 20cm. 
 
 Desmoid tumour with AFL presents a management challenge in clinical 
practice. Cytotoxic chemotherapy cannot be used in this situation due to 
underlying sepsis. Surgery is often complex requiring resection of large 
segment of bowel, defunctioning or bypass. 
 
6.6  Summary 
 
The main limitation of this study is the small patient number, however, 
desmoid tumours are rare and only a small number of desmoid patients 
present with this condition. 
 
Based on the outcome of this study, a management algorithm for IAD patients 
with an air-fluid level is proposed (Figure 6.2). A small number of patients 
who are symptomatic but not severely septic (two in this cohort) can be 
managed with antibiotics alone. Patient presenting with sepsis and IAD with 
AFL, but not peritonitic on clinical assessment, can be managed with 
radiologically or surgically placed drains. Patients with suspicion of a hard 
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DT, where the DT has more than a two-centimeters solid rim on ultrasound or 
CT scanning, or anatomical access is hazardous, are difficult to drain 
percutaneously. In addition muliti-locular collections and viscosity of these 
fluid may also hinder drainage. Open drain placement can overcome some of 
these obstacles. Failure of drainage or generalized peritonitis necessitates an 
open surgical approach usually requiring excision or drainage with or 
without defunctioning/exclusion.  
 
 
 
Fig 6.2 – Management algorithm for intra-abdominal desmoids with air-fluid levels 
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6.7 Conclusion 
 
Management of IAD with air fluid level is complex often requiring surgery. 
However some patients can be managed with a more conservative approach 
of antibiotics alone or antibiotics combined with percutaneous drainage 
avoiding complex and potentially morbid surgery. We suggest managing 
these conditions in specialist centre on individual assessment basis and with 
involvement of multidisciplinary team. 
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PART 4 – LABORATORY STUDIES 
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Chapter 7 
 
 
 
 
 
 
Laboratory materials and methods 
 
 
 
7.1 Samples 
 
Three desmoid cell lines (D1, D2 and D3) and one fibroblast cell line (C1) 
derived form patient with FAP but without desmoid have previously been 
established. These cell lines were established from tumour and tissue biopsy 
from FAP patients with prior ethical approval (Harrow Research and Ethics 
Committee, REC ref No: 08/H0719/75; 09/H0709/13) and patient consent 
(Sinha et al, 2010). These were first subjected to ‘second hit’ APC mutation 
analysis (Chapter 8). 
 
The confirmed FAP desmoid cell line (D3) along with FAP fibroblast control  
(C1) and a commercially available established human fibroblast cell line from 
human foreskin  (C2) were then used for choline metabolism and Wnt signal 
pathway studies. Formalin fixed paraffin embedded sections of the same 
desmoid tumour were used for immunohistochemistry. The desmoid tumour 
sections were obtained from the histopathology department at St Mark’s 
Hospital. 
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7.2 Reagents 
 
 
 
7.2.1 Tissue culture reagents 
 
 
 
All reagents were sterile and of tissue culture grade.  
Dulbecco’s Modified Eagle’s Medium (DMEM) containing, low glucose, 
 
pyruvate, L-glutamine (Cat no: 31885-023, GIbco Invitrogen, Paisley, UK) 
 
10% Foetal Bovine Serum (FBS, First Link, UK) 
 
Antibiotics (100Unitsml-1 penicillin, 100µgml-1streptomycin, Invitrogen, UK) 
 
0.25% Trypsin-EDTA, Gibco (Invitrogen, UK) 
 
Phosphate buffered saline (PBS), Gibco (Invitrogen, UK) 
 
Bambanker Cell Freezing Media (Anachem,UK) 
 
All plastic-ware for TC (Invitrogen, UK) 
 
 
 
7.2.2 DNA purification reagents  
 
10mM NaCl/10mM EDTA  
75mM NaCl/25mM EDTA  
10% SDS  
20mg/ml Proteinase K  
25:24:1 phenol:chloroform:isoamyl alcohol  
24:1 chloroform:isoamyl alcohol extraction mix  
3M sodium acetate (NaOAc)  
100% ethanol  
TE buffer  
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7.2.3 RNA purification reagents 
 
Purification of total RNA from cells were performed using RNeasy Mini Kit 
(Qiagen, UK) 
 
7.2.4 cDNA synthesis reagents 
 
First strand cDNA was synthesised by using SuperscriptTM First–Strand 
Synthesis System for RT-PCR (Invitrogen, UK). 
 
7.2.5 Real time polymerase chain reaction (RT–PCR) reagents 
 
5X Green Go Taq® Flexi buffer (Promega UK) 
25mM MgCl2 
PCR Nucleotide mix (Promega, UK) 
Forward Primer 
Reverse Primer 
GoTaq® DNA Polymerase (Promega, UK) 
Nuclease-Free Water 
Agarose (Invitrogen, UK) 
Ethidium Bromide 
Loading sample buffer  
500bp and 1Kb DNA ladders 
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7.2.6 Quantitative RT-PCR (qPCR) reagents 
 
qPCR for choline kinase alpha (CHKA) expression was performed by using 
Platinum@SYBR@Green qPCR Supermix-UDH with ROX (Invitrogen). 
 
qPCR for WNT11 and AXIN2 expressions were performed by using 
PerfeCTa® SYBR® Green SuperMix, Low ROX™ (Quanta Biosciences). 
 
7.2.7 SDS-PAGE Reagents/ Western Blot Reagents 
 
Tetramethylethylediamine (TEMED) 
30% (w/v) Acrylamide/bis-acrylamide  
10% Ammonium persulphate (APS) 
10% Sodium Dodecyl Sulphate (SDS) 
1.5M Tris, pH 8.8 (resolving gel) 
1.0M Tris pH 6.8 (30.285g TRIS, 200ml ddH2O) (stacking gel) 
Double distilled water (ddH2O) 
Prestained Precision Plus protein standard 
Protran Nitrocellulose membrane (GE Healthcare, UK) 
Stripping Buffer 
Blocking solution (3% Albumin, 1% Albumin from chicken egg white in 
TBST) 
10x Running Buffer (30.3g TRIS, 188g Glycine in 1l ddH2O). For 1x solution 
10ml 10% SDS was added. 
Transfer Buffer (5.82g TRIS, 2.93g Glycine, 3.75ml 10% SDS, 200ml MeOH, 
ddH2O was added to make 1l solution) 
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ECL Western Blotting Substrate (Thermo Fisher Scientific, UK) 
Amersham Hyperfilm ECL (GE Healthcare, UK) 
 
7.2.8 β-catenin indirect immunofluorescence staining reagents 
 
4% Paraformaldehyde 
Purified mouse anti-β-catenin (BD Transduction Laboratories, UK, 1:400 
dilution) 
Alexa fluor-488 goat anti-mouse IgG (Invitrogen, UK, 1:500 dilution) 
DAPI staining for cell nuclei (Sigma- Aldrich, UK)  
 
7.2.9 Immunohistochemistry reagents 
 
Histoclear 
100% Ethanol, 70% Ethanol, ddH2O, 1.5% H2O2 in methanol 
10mM Sodium Citrate Buffer, pH 6 
1x phosphate buffered saline (PBS) 
1.5% Horse Serum 
VectaStain Elite ABC reagent 
DAB (3.3’ Diaminobenzidine) substrate (DAKO, UK) 
Haematoxylin 
Pertex Mounting Media (Leica Biosystems, UK) 
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7.3 Antibodies 
 
Summary of antibodies used for the studies is listed below. 
 
 
Antigen 
 
Specificity 
 
Antibody 
type 
 
Use 
 
Dilution 
 
Raised 
in 
 
Company 
 
Wnt-11 
 
Human/Mouse 
 
PAb 
IC 
IH 
WB 
 
1:1000 
1:1000 
 
Goat 
 
R&D System 
 
β-catenin 
 
Human, Dog, Rat, 
Mouse, Chick 
 
MAb 
WB 
IC 
IH 
 
1:500 
 
Mouse 
 
BD Transduction 
 
HSP60 
 
Human, Mouse, 
Rat, bovine, 
canine, chicken, 
drosophila, guinea 
pig, hamster, 
monkey, pig, 
rabbit, sheep, 
xenopus 
 
MAb 
 
WB 
 
1:1000 
 
Mouse 
 
Stressgen  
 
 
Peroxidase 
conjugated anti-
mouse 
 
 
Mouse 
 
 
PAb 
 
 
WB 
 
 
1:10000 
 
 
Donkey 
 
 
Jackson 
Immunoresearch 
 
HRP conjugated 
anti-goat 
 
 
Goat 
 
PAb 
 
WB 
 
1:10000 
 
Donkey 
 
Santa Cruz Biochem 
 
Table 7.1 - Summary of antibodies 
 
7.4 Primers for RT-PCR and qPCR 
 
AXIN2 (for RT-PCR) 
Forward: TTATGCTTTGCACTACGTCCCTCCA  
Reverse: CGCAACATGGTCAACCCTCAGAC  
 
AXIN2 (for qPCR) 
Forward: AAGTGCAAACTTTCGCCAAC 
 
Reverse: ACAGGATCGCTCCTCTTGAA 
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WNT11 (for RT-PCR) 
Forward: CGATGCTCCTATGAAGGTGAAA  
Reverse: CTTCCGTTGGATGTCTTGTTG 
  
WNT11 (for qPCR) 
Forward: AGACCGGCGTGTGCTATG 
 
Reverse: CACCTGTGCAGACACCAGAC 
 
CHKA (for qPCR) 
Forward: CGGAAGTATCCCACCAAGAA    
Reverse: TCCCCAGAGGAAATGAGATG 
 
GAPDH (for RT-PCR control) 
Forward: TGTTGCCATCAATGACCCCTT 
Reverse: CTCCACGACGTACTCAGCG 
 
PPIA (house keeping gene for CHKA qPCR) 
Forward: CTGCACTGCCAAGACTGA    
Reverse: CATTCCTGGACCCAAA 
 
36B4 (house keeping gene for AXIN2 and WNT11 qPCR) 
 
Forward: GTGTTCGACAATGGCAGCAT 
 
Reverse: AGACACTGGCAACATTGCGGA 
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7.5 General methods 
 
7.5.1 Cell culture 
 
The frozen cells were thawed in a water bath at 370C and immediately 
transferred to a 10cm petri dish containing cell culture medium (DMEM with 
15% FCS with penicillin V and streptomycin). Cells were re-fed every 48 
hours. After confluence, cells were detached from the culture plate by adding 
3ml trypsin solution and four times the volume of culture medium (12ml) was 
then added to neutralise trypsin. The cell suspension was then centrifuged at 
1000rpm for 5 minutes, the supernatant was discarded and the cell pellet was 
re-suspended in culture medium. Cells were then divided and passaged at 2 x 
105 cells per plate.  
 
7.5.2 Cell freezing 
 
After centrifuging the cells as described in section 7.5.1, the cell pellet was re-
suspended in 1ml cell freezing solution and transferred in a cryovial. The 
cryovial was then gradually frozen at -800C and subsequently stored in liquid 
nitrogen after 48 hours. 
 
7.5.3 DNA extraction 
 
Pelleted cells were first re-suspended in 10mM NaCl/10mM EDTA (500µl) 
and centrifuged at 13000rpm for one minute. The supernatant was discarded 
and 75mM NaCl/25mM EDTA (500µl), 10%SDS (50µl) and Proteinase K (25µl) 
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was then added to cells and left for overnight incubation at 370C. Next day 
phenol/chloroform/isoamyl alcohol (25:24:1, 500µl) was added to the 
solution, vortexed briefly and centrifuged at 13000rpm for 1 minute. The top 
layer of the solution was then carefully transferred to a new tube and 
chloroform/isoamyl alcohol (24:1, 500µl) was then added to the solution, 
mixed well and centrifuged at 13000rpm for 1 minute. The top layer of 
supernatant was then carefully transferred to a new tube and 100% EtOH 
(1ml) and 3M NaOAc (50µl) was then added to the tube and gently mixed 
until precipitated DNA could be seen floating. The solution was spun down 
at 13000rpm for 2 minutes; the supernatant was carefully discarded without 
disturbing the pellet. 70% ethanol (1ml) was then added to the pellet, 
vortexed very gently and spun down at 13000rpm for 2 minutes. The 
supernatant was discarded and the pellet was resuspended in 50µl of TE and 
incubated at 560C for 1-2 hours to fully dissolve the DNA. The concentration 
of DNA was measured using a Nanodrop spectrophotometer and further 
diluted by adding TE to obtain a final concentration of 50ngµl-1. 
 
7.5.4 Purification of total RNA 
 
Cells were grown to confluence and pelleted as described in section 7.5.1.  
Pelleted cells were lysed by adding buffer RLT (Qigen) (350µl) and 
homogenised by centrifugation at 30000rpm for 2 minutes in a QIA shredder 
spin column placed in a collection tube. 70% alcohol (350µl) was added to the 
homogenised lysate and mixed by pipetting. The sample (700µl) was then 
transferred to an RNeasy spin column placed in a collection tube and 
centrifuged for 15s at 15000rpm and the flow-through was discarded. On-
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column DNA digestion was performed by washing the RNeasy spin column 
membrane first with buffer RW1 (Qigen) (350µl) and centrifuging at 
15000rpm for 15s and then adding DNase I incubation mix to the spin column 
membrane at room temperature for 15 minutes. The membrane was further 
washed by adding buffer RW1 (350µl) and buffer RPE (Qigen) (500µl) and 
centrifuging each time at 15000rpm. RNA was then eluted on a collection tube 
by adding 30µl of RNase-free water to the spin column membrane and 
centrifuging at 15000rpm for one minute. Total RNA thus eluted was then 
quantified by measuring in a NanodropTM spectrophotometer (Thermo 
Scientific). The quality of the isolated RNA was determined by measuring the 
optical density (OD) in the Nanodrop. By determining the 260/280 ratio > 2, 
pure RNA isolation and low protein contamination was ensured.  
 
7.5.5 cDNA preparation 
 
The RNA/primer mixture was first prepared by adding 3µg RNA, 1µl 10mM 
dNTP mix, 1µl Random Hexamer (50ng/µl) and DEPC-treated water to make 
10µl total volume and incubated at 650C for five minutes and immediately 
cooled on ice for one minute. The reaction mix prepared by adding 2µl 10x RT 
buffer, 4µl 25mM MgCl2, 2µl 0.1M DTT, 1µl RNaseOUTTM (40U/µl) was then 
added to RNA/primer mixture and incubated at 250C for 10 minutes. The 
mixture was further incubated at 420C for 50 minutes after adding 1µl 
SuperScriptTM II RT and then at 700C for 15 minutes and chilled on ice. cDNA 
synthesis was completed by adding 1µl RNase H to the mixture and 
incubating at 370C for further 20 minutes. The synthesised cDNA was either 
used immediately for PCR or stored at - 200C for future use. All the thermal 
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cycles described were performed using Gene Amp@ PCR System 2700 
(Applied Biosystems). 
 
7.5.6 RT-PCR 
 
2µl cDNA was added to 23µl master mix to make 25µl PCR solution. The 
master mix was prepared by adding the following reagents. 
 
5x Green Go Taq Buffer 5µl 
25µm MgCl2 1.5µl 
PCR nucleotide mix (dNTPs) 0.5µl 
Forward primer 0.5µl 
Reverse primer 0.5µl 
Go Taq polymerase 1.25µl 
RNase free water 13.75µl (to total volume 25µl) 
 
RT-PCR was carried out using Gene Amp@ PCR System 2700 (Applied 
Biosystems) by using the following thermal cycles: 
 
940C for 5 minutes 
(940C for 30s, 60 0C for 30s, 720C for 30s) for 30 cycles 
720C for 10 minutes  
 
5µl aliquots of the RT-PCR product were then resolved on a 1% agarose gel 
containing ethidium bromide. 500bp and 1kb DNA ladders were included on 
each gel. 
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7.5.7 Quantitative Real Time PCR (qPCR) 
 
qPCR for CHKA expression was performed in a 7900HT Fast Real Time PCR 
System (Applied Biosystems, UK) and analysed using Applied Biosystems 
SDS software V2.4. Platinum@SYBR@Green qPCR Supermix-UDH with ROX 
(Invitrogen, UK) and invitrogen probes specific for CHKA were used as per 
manufacturer instructions. PPIA was used as house keeping gene. Reactions 
were carried out in triplicate, each in 10µl volumes. Thermal cycling condition 
for qPCR was as follows: 2 minutes each at 500C and 950C; then 3s at 950C and 
30s at 600C for 40 cycles followed by dissociation for 15s each at 950C and 
600C.  
 
qPCR for AXIN2 and WNT11 expressions were performed in a ViiA™ 7 
System (Applied Biosystems) using using PerfeCTa® SYBR® Green 
SuperMix, Low ROX™ (Quanta Biosciences). 36B4 gene was used as 
housekeeping gene. Reactions were carried out in triplicate, each in 25µl 
volumes. Thermal cycling condition for qPCR was as follows: 2 minutes at 
950C; then 15s at 950C and 30s at 600C for 40 cycles followed by dissociation 
for 15s each at 950C and 600C.  
 
7.5.8 Protein extraction 
  
Lysis buffer was first prepared by adding 1ml 1x RIPA buffer, 10µl Protein 
Inhibitor Complex (PIC) and 4µl EDTA reagents. 500µl of the lysis buffer was 
then added to the confluent cells in a 10cm culture plate and the lysate was 
collected by scraping. The solution was then centrifuged at 13000rpm for 30 
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minutes at 40C. The supernatant was collected in a tube and either used 
immediately for western blot analysis or stored at -200C for future use. 
 
RIPA Buffer (Radio Immuno Precipitation Assay buffer) 
 
150mM sodium chloride 
1.0% NP-40 or Triton x-100 
0.5% sodium deoxucholate 
0.1% SDS (sodium dodecyl sulphate) 
50mM Tris, pH 8.0 
 
7.5.9  Western blotting 
 
7.5.9.1  Sample preparation 
 
Protein samples were added to 2x Laemmli buffer (120mM Tris pH 6.8, 4% 
SDS, 10% β-mercaptoethanol, 10% glycerol, 0.004% bromophenol blue), boiled 
for 5 minutes at 950C. 
 
7.5.9.2  Sodium dodecyl sulphate polyacrylamide gel electrophoresis  
(SDS-PAGE) 
 
For gel recipes, please see section 18.53 of Molecular Cloning (Sambrook et al, 
1989). Proteins were separated on 8% Tris-Glycine SDS polyacrylamide gels. 
5µl pre-stained precision plus protein standards were loaded alongside the 
samples to allow determination of protein band sizes. Gels were run in 
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protein gel tanks (Bio-Rad, UK) in 1x Tris-glycine running buffer for 
approximately 2 hours at 80mV. 
 
1xTris-glycine running buffer 
 
25mM Tris base 
190mM glycine 
0.1% SDS 
 
7.5.9.3  Transfer of proteins to nitrocellulose membrane 
 
After electrophoresis, the separated proteins were transferred onto 
nitrocellulose transfer membrane (ProtranTM, Whatman, GE Heathcare) in 
transfer buffer using a Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad, UK) at 
10V for 30 minutes. After transfer the membrane was washed with 1x TBST 
and blocked at room temperature for one hour in blocking solution. 
 
Primary antibody diluted in blocking solution was applied directly to the 
membrane and the membrane was incubated at 40C overnight on a slow 
rocker. The membrane was then washed for 3x 10 minutes in 1x TBST and 
appropriate horseradish peroxidase (HRP) conjugated secondary antibody 
diluted in blocking solution was added to it. The membrane was then 
incubated at room temperature for at least one hour and washed in 1x TBST 
for 3x 10 minutes. Enhanced chemiluminiscence (ECL) substrate (Amersham) 
was applied to the membrane and the protein bands were detected by X-ray 
film.                                                           
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Transfer Buffer 
 
5.82g Tris base 
2.93g Glycine 
3.75ml SDS (10%) 
200ml methanol 
Water up to 1L 
 
1x TBST (Tris-Buffered Saline with Tween) 
 
25mM Tris pH 7.4 
150mM NaCl 
2mM KCl 
0.1% Tween-20 
 
7.5.10 β-catenin immunocytochemistry  
 
Cells grown on coverslips were first washed with PBS 2 times and fixed with 
4% formaldehyde for 15 minutes at room temperature. The cells were then 
washed 3x 5 minutes with PBS and permeabilised with 0.1% Triton-x100 in 
PBS for ten minutes at room temperature. The cells were further washed with 
PBS 3x 5 minutes and blocked with 1% BSA/0.1% Triton/PBS (PBST-BSA) for 
one hour at room temperature. The appropriate dilution of primary antibody 
in PBST-BSA was then added to the cells and incubated overnight at 40C. Next 
day the cells were washed with PBS 3x10 minutes and incubated with 
appropriate dilution of secondary antibody in PBST-BSA for one hour at room 
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temperature in the dark (foil covered). The coverslips were then washed with 
PBS 3x10 minutes and mounted onto slides using a wet mount technique 
(with DAPI to stain nuclei) and the slides were analysed using a Zeiss 
Fluorescent microscope. 
 
7.5.11 Immunohistochemistry 
 
7.5.11.1 Dewaxing 
 
All the slides were placed in a metal slide holder and placed in each of the 
following solutions for five minutes: 
 
Histoclear 
Histoclear 
100% ethanol 
100% ethanol 
70% ethanol 
The slides were then placed in a pot of distilled water for three minutes. 
 
7.5.11.2 Antigen retrieval 
 
The slides were transferred to a plastic holder containing in pre-warmed Tri-
sodium citrate solution (pH 6) and microwaved (750W) for 6 minutes. The 
box containing the slides were then cooled down by placing in a box of 
distilled water placed on a shaker for five minutes at room temperature. 
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Tri-sodium citrate solution 
 
0.5g Tri-sodium citrate crystals 
500ml distilled water 
HCl added to pH 6 
 
7.5.11.3 Blocking endogenous peroxidase activity 
 
The slides were placed in 1.5% H2O2 in methanol (50ml Methanol, 750µl H2O2) 
for 30 minutes and washed three times in PBS. 
 
7.5.11.4 Primary antibody staining 
 
The slides were first blocked with 1.5% horse serum for one hour. The 
appropriate dilution of primary antibody prepared in horse serum was then 
added to the slides and the slides were incubated overnight at 40C.  
 
7.5.11.5 Secondary antibody staining 
 
The slides from step 7.5.10.4 were first washed 3x5 minutes in PBS solution. 
The appropriate dilution of secondary antibody (Vector laboratory pan 
specific biotinylated anti-mouse, anti-rabbit, anti-goat antibody) in horse 
serum was then added to the slides. The slides were left at room temperature 
for 30 minutes and washed 3x5 minutes in PBS solution. The slides were then 
stained with VECTASTAIN® Elite ABC reagent (Vector laboratories, UK) for 
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30 minutes at room temperature. After 30 minutes the slides were washed 3x5 
minutes in PBS solution. 
 
7.5.11.6 Diaminobenzidine (DAB) reaction 
 
The slides were stained for 2-5 minutes using high-sensitivity substrate 
chromogen system (liquid DAB substrate, Dako) while constantly checking 
under microscope for development of appropriate level of chromogen signal 
intensity (brown stain). The slides were then washed twice with distilled 
water and counterstained in Haematoxylin for 1-2 minutes. The slides were 
washed again two times in distilled water. 
 
7.5.11.7 Dehydration 
 
The dehydration step was completed by dipping the slides in the following 
solutions for 5 minutes each  
 
70% Ethanol 
100% Ethanol 
100% Ethanol 
Histoclear 
Histoclear 
 
The slides were then immediately mounted using the pertex mounting 
medium (Leica Biosystems) and studied under the microscope. 
	   141	  
Chapter 8 
 
 
APC mutation analysis in FAP desmoids and fibroblast 
cell lines 
 
8.1  Background and aims 
 
Cell culture is a commonly used laboratory technique to characterise animal 
cells and investigate tumorigenesis. Culture of desmoid cell lines provides a 
unique opportunity to investigate these rare tumours in vitro. However, there 
is no commercially available established desmoid tumour cell line. Previous 
attempts at primary cell culture of desmoid have proven difficult due to 
overgrowth of fibroblasts (Sturt et al, 2004). Recently Sinha et al described a 
model of FAP desmoids and reported successful establishment of primary 
desmoid cell lines from surgical biopsy of tumours (Sinha A, 2010). 
Establishment of desmoid cell lines as opposed to fibroblast overgrowth was 
confirmed by the presence of nuclear β-catenin in the desmoid cell lines 
(Sinha A, 2010). β-catenin is an important regulator of the Wnt signaling 
pathway and is upregulated in FAP desmoid cells owing to mutations in both 
alleles of the APC gene. 
 
The studies described in this chapter and subsequent chapters uses primary 
desmoid tumour cell lines created and stored by Sinha et al. A major problem 
in primary cell lines established from desmoid tumour biopsy is the 
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overgrowth of background fibroblasts with subsequent passage of cells in the 
culture. To clarify this possibility, this study aimed to confirm the true 
selection of desmoid cells in culture by performing whole sequence APC gene 
mutation analysis.  
 
According to Knudson’s ‘second hit’ hypothesis, both alleles of APC should 
be mutated in a desmoid tumour. Previous studies have demonstrated that 
desmoid in FAP are monoclonal proliferations, and the ‘second hit’ somatic 
mutations have been identified and characterised in these tumours 
(Middleton et al, 2000; Lamlum et al, 1999). Hence, the identification of two 
mutations in the cells in culture would confirm that the growing cells are true 
desmoid cells and not the overgrowth of contaminating fibroblasts.  
 
8.2  Materials and methods 
 
8.2.1  Samples 
 
Three primary desmoid tumour cell lines (D1, D2 and D3) and one primary 
FAP fibroblast cell line (C1) established and stored by Sinha et al (2010) were 
subjected to APC mutation analysis. The primary desmoid cell lines were 
established from surgical excision of desmoid tumours and the primary 
fibroblast cell line was established from mesenteric biopsy of a patient with 
FAP but free of desmoid tumour. The cell lines were established using an 
explant technique (Sinha A, 2010). Ethical approval from the Harrow 
Research and Ethics Committee along with research and development 
approval from the North West London Hospitals NHS Trust and informed 
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consent from the patients were obtained for the study. Table 6.1 outlines the 
patient characteristics and known germline APC mutations in the patients. 
 
 
Samples 
 
 
Patient age (Yrs) 
 
Tumour Site 
 
Mutation 
 
D1 
 
22 
 
AWD 
 
c.4666dupA 
 
p. Thr1556Asn fsX3 
 
D2 
 
27 
 
IAD 
 
c.4226delC 
 
 
D3 
 
34 
 
AWD 
 
c.3393G>T 
 
 p.Glu1132X 
 
C1 
 
 
27 
 
Biopsy from 
mesentery 
 
c.4226delC 
 
Table 8.1 - Patient characteristics and known germline mutations 
 
8.3  Cell culture 
 
Frozen vials of the desmoid cell lines (D1, D2 and D3) and fibroblast cell line 
(C1) were thawed and cell culture was performed as described in section 
7.5.1. Two million cells per cell line were pelleted and subjected to DNA 
extraction for APC mutation analysis. 
 
8.4 DNA extraction 
 
DNA was extracted from the samples using the protocol described in section 
7.5.3. 
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8.5  High-throughput method for whole gene sequencing of APC 
 
A high-throughput PCR method was used for sequencing all fifteen coding 
exons of the APC gene for full mutation screening. The primers used for PCR 
and sequencing was optimised to amplify at one temperature. Primer 
sequence used for this experiment is listed below: 
 
APC exon1 Forward:  GAGTTTTGTTTCCTTTACCCCTTTC 
          Reverse:  AAAGTGTCTTACCTCAAGTTTACAAGA  
 
APC exon2 Forward:  TATATAAGGTGCGTGCTTTGAGAGT  
          Reverse:  AAATCGAGAGAAGCTGTACTTGGA  
 
APC exon3 Forward:  TGTTTTCAGTCATGTATATTTGTGG  
          Reverse:  AAATGCAAAATGCTCTAAGTGTTA  
 
APC exon4 Forward:   TGCTCTTCTGCAGTCTTTATTAGC 
          Reverse:  AGGCCTAAAGTTGGGTAAAACATA 
 
APC exon5 Forward:  CACCATGACTGACGTATTTGCTTA  
          Reverse:  AATAGAGCCAAAATAAACACAGCC  
 
APC exon6 Forward:  CATAACCCTGAGCTTTTAAGTGGT  
          Reverse:  TGTAAACTGACAGCTAAAGTAAGGTATCTA  
 
APC exon7 Forward:  CTACACCATTTTTGCATGTACTGA  
          Reverse:  CCATCTTGCTTCATACTTTTCTGA 
  
APC exon8 Forward:  CAGACACTTCATTTGGAGTACCTTA  
          Reverse:  TGTCTTAGCAAAGTAGTCATGGCA  
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APC exon9  Forward:   CACTGATTACTTCATCCTGGAAAG 
           Reverse:  ACATTTGCTTTGAAACATGCAC  
 
APC exon10 Forward:  TCCACTAAAATTCCGTGAATTAGG  
           Reverse:  GATAACAGAAGTTGGTGGCCTTA  
 
APC exon11 Forward:  CTGGCATAAAATGGAATAATTGTC  
           Reverse:  GATAAGCGAATGTGAAGCACAGG  
 
APC exon12 Forward:  AATAAAGCTTGGCTTCAAGTTGTC 
           Reverse:  AGATTGCACAACTGCCCTCTAAG 
 
APC exon13 Forward:  GCTAGCCAGAATTTCTTTCTTAATAG  
           Reverse:  GGTAAGAAATTAGGAAATCTCATGG 
 
APC exon14 Forward:  TTCTTAATTTACCAGTGAGGGAC 
           Reverse:  GGCTACACCTCTCAACTATAATTTGC 
 
APC exon15_1 Forward:  GGAGATGTGGAATACTTGGAATTTAT 
             Reverse:  ATTATCATCATGTCGATTGGTGTC 
 
APC exon15_2 Forward:  CAATATTATGTCTCCTGGCTCAAG 
             Reverse:  AACATGTCCTATTTGAATTTTCCG 
 
APC exon15_3 Forward:  AAGAAGTGTCAGCCATTCATACCT  
             Reverse:  ACCTGTATGGAGAAACACATTCCT  
  
APC exon15_4 Forward:  CCGACCTAGCCCATAAAATACATA  
             Reverse:  CATATGTTCGGTTTTACTGCTTTG  
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APC exon15_5 Forward:  AATGTAAGCCAGTCTTTGTGTC  
             Reverse:  AGTCTGCTGGATTTGGTTCTA  
 
APC exon15_6 Forward:  ATCAGCTGAAGATGAAATAGGATG  
             Reverse:  CATTTACTGCAGCTTGCTTAGGT  
 
APC exon15_7 Forward:  CTCAAACCAAGCGAGAAGTACC  
             Reverse:       ATTTCAATATCATCATCATCTGAATCATCT  
 
APC exon15_8 Forward:       TAAGAATAATGCCTCCAGTTCAGG  
             Reverse:  CTGGTCCATTATCTTTTTCACACG  
  
APC exon15_9 Forward:  TTCCTACAGAAGGCAGAAGTACAG  
             Reverse:  CAGTAAGGAGTTCCTTCAATAGGC  
 
APC exon15_10 Forward:   CCACAAAATACTGAATATAGGACACG 
              Reverse:      GAGGTTTACTTGGTTCTCCCTGT  
 
APC exon15_11 Forward:   ACCCATACTTCAGAAACAATCCAC  
              Reverse:      CAGCAGCAGCTTGATGTAAACTAC 
 
APC exon15_12 Forward:   GTGAAGATCTGACACTTGATTTG 
              Reverse:      AACAGGGCTTAATTCTGATTTCAC 
 
APC exon15_13 Forward:       TATTCCAGGAGTTCGAAATAGCTC  
              Reverse:       TGTTTGTTTGGTAAGGTTCTGTTG  
 
APC exon15_14 Forward:       TTATCTCAACTTCCAAGGACATCA  
              Reverse:       TCAGAATGAGACCGTGCAATATC  
 
APC exon15_15 Forward:       TCATTTGAATCTCTTTCTCCATCA  
              Reverse:       GTTAATGGGACAGTCCTCAATTCT  
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APC exon15_16 Forward:   CATGTGAACTCTATTTCAGGAACC  
              Reverse:      GCTTGGGTTGTAATTAAAAGGAGT  
APC exon15_17 Forward:   CAAAATAATCCTGTCCCTGTATCA  
              Reverse:      AGCAATAATTAAAGGAAGTTGGGA  
 
 
To perform the PCR, all the primers were first spotted on 96-well plates using 
a robotic setup and a predefined protocol. PCR mix was made by adding 
250µl Megamix royal, 25µl DNA (50ngµl-1) and 375µl water for injection. The 
Tecan Evo 150 robot and endoware software package was used to aliquot 
predetermined amount of PCR mix to the primer spotted 96-well PCR plates. 
The PCR was performed with following set up in MJ thermo cycler (MJ 
Research, USA).  
 
950C for 5 minutes  
940C for 1 minute, 600C for 1 minute, 720C for 1 minute (30 cycles) 
720C for 10 minutes 
 
The PCR product was then run on a 2% agarose gel to confirm that the 
reaction had worked. Individual PCR reactions were repeated for any failed 
reactions. 
 
For DNA sequencing, the unconsumed primers and dNTPs were first 
removed by using ExoSAP-IT reagent. For this 5µl of PCR product was added 
to 2µl ExoSAP-IT and incubated at 370C for 15 minutes and then 800C for 15 
minutes. The solution was then cooled to 40C.  
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For individual sequencing plates, the sequencing mix was first prepared by 
adding Big Dye v1.1 (51µl), Big Dye buffer (178.5µl) and water for injection 
(735µl). Separate forward and reverse sequencing primer spotted plates were 
thawed and 9.5µl of sequencing mix was added to each well of the primer 
spotted plates. 0.5µl of post ExoSAP PCR product was then added into the 
sequencing plate and the thermocycle reaction was performed using the 
following set up: 
 
960C for 1 minute,  
960C for 10s, 500C for 5s, 600C for 4 minutes (25 cycles) 
Hold at 40C 
 
Unincorporated Dye (ddNTPs) was removed from the sequencing product by 
using DyeEx 96 plate. The sequence was then run on an ABI 3730 sequencer 
using the standard sequencing protocol provided by Applied Biosystems.    
 
DNA extraction, PCR and APC Sequencing described above was performed 
at the Kennedy Galton Centre, Northwick Park and St Mark’s Hospital. 
 
8.6  Results 
 
8.6.1  APC mutation analysis in desmoid tumour cell lines (D1, D2 and D3)  
 
The whole APC gene sequencing of the three primary desmoid tumour cell 
lines identified the germline mutations already known in the respective 
patients. However, a ‘second hit’ somatic mutation was identified only in the 
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cell line D3. Fig 8.1 demonstrates the result of APC sequencing of the D1 cell 
line and Fig 8.2 (a, b) demonstrates the result of APC sequencing of the D3 cell 
line. 
 
 
 
Fig 8.1 - DNA sequencing showing duplication of adenine (red circle) at nucleotide sequence 
no 4666 (c 4666dupA). The result of mutation analysis identified the known germline 
mutation in this sample; however, no ‘second hit’ somatic mutation was detected 
APC	  reference	  sequence	  –	  Forwards	  direction	  	  	  Sample	  –	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  direction	  	  	  Difference	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  –	  F	  	  	  	  Difference	  trace	  –	  R	  	  	  	  Sample	  –	  reverse	  direction	  	  APC	  reference	  sequence	  –	  reverse	  direction	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A 
 
 B 
 
Fig 8.2 - DNA sequencing showing glutamine replaced by thymine at nucleotide sequence 
3393 (germline mutation, codon 1132) (A, red circle) and deletion of adenine at nucleotide 
sequence 4312 (somatic mutation, codon 1438) (B, red circle). The whole exon APC 
sequencing detected the known germline mutation and also a second hit somatic mutation in 
this sample 
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8.6.2  APC mutation analysis in FAP fibroblast cell line (C1) 
 
APC sequencing only detected the known germline mutation in the patient. 
No other mutation in APC was detected. Fig 6.3 shows the result of mutation 
analysis in this sample. 
 
 
Fig 8.3 - DNA sequencing showing deletion of cytosine (red circle) at nucleotide sequence 
4226  (c.4226delC) 
 
8.7 Discussion 
 
APC is a tumour suppressor gene, and consistent with Knudson’s two-hit 
hypothesis, both alleles are mutated in FAP associated desmoid tumours; one 
in the germline and the other in the soma (Knudson, 1985). A relationship 
between the first (germline) and second (somatic) hit in desmoids has been 
previously described: desmoids from patients with germline mutations 5’ to 
APC	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  –	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  Difference	  trace	  –	  F	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codon 1400 are more prone to have a truncating somatic mutation 3’ to codon 
1400 and desmoids carrying a germline mutation 3’ to 1400 are more likely to 
have loss of heterozygosity (LOH) as their second hit. Consistent with this 
hypothesis, desmoid cells in culture should also harbour two mutations in 
APC, one germline and one somatic mutation. In 2006 Martinico et al 
published the result of endostatin gene therapy in desmoid tumours by using 
primary desmoid tumour cell lines established form FAP patients. In this 
study, the selection of desmoid tumour cells in culture was confirmed by 
detection of two APC mutations (germ line and somatic) in the cells in culture 
(Martinico et al, 2006). 
 
The results of APC mutation in the current study show that two of the cell 
lines established from desmoid tumour (D1 and D2) did not harbour an 
identifiable second hit somatic mutation. The likely explanation of this 
finding is that the desmoid cells have been overgrown and replaced by 
fibroblasts in these cell lines. As will be the case with every cell in the FAP 
patient, such fibroblast cells in culture harboured the known germline 
mutation. As expected, the fibroblast cell line C1 only harboured the known 
germline mutation. 
 
On the other hand, desmoid tumour cell line D3 was found to harbour two 
mutations. One of these mutations (germline) was on codon 1132, which is 
not in the ‘desmoid-prone mutation’ region. Consistent with the known 
desmoid genetic and somatic mutation relationship, as explained above, 
however, the second somatic mutation in this cell line was detected in codon 
1438, within the ‘desmoid-prone mutation’ region.  
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8.8 Summary 
 
In summary the result of the APC mutation study in D3 cell line confirms that 
true desmoid cells are present in the culture and therefore D3 is a true 
desmoid tumour cell line.  
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Chapter 9 
 
 
Study of choline metabolism in desmoid tumour in FAP  
 
9.1 The choline metabolism pathway (Kennedy Cycle)  
 
Choline is an essential nutrient in humans, primarily supplied by diet and 
absorbed in the intestine. It is a precursor for the biosynthesis of choline 
phospholipids such as phosphatidylcholine (PC), which is required for the 
formation and maintenance of cell membrane. In the Kennedy cycle, choline 
first enters the cell through the plasma membrane by passive transport 
diffusion or by choline-specific transport. It is then phosphorylated by the 
enzymatic effect of choline kinase (ChoK), resulting in phosphocholine 
(PCho). PCho is converted to CDP-Choline through the action of CDP-
phosphorylcholine cytidyltransferase and subsequently to 
phosphatidylcholine (PC) through the action of DAG-choline 
phosphoryltransferase. Phosphatidylcholine-specifïc phospholipase D (PC- 
PLD) hydrolyzes PC to generate choline in addition to phosphatidic acid 
(PA), thus completing the cycle. The Kennedy cycle is outlined in Fig 9.1. 
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Fig 9.1 - Outline of the Kennedy pathway (adapted from Gallego-Ortega et al. Advances in 
Enzyme Regulation; 51 (2011), 183-194) 
 
9.2 Choline metabolism in tumours 
 
A high concentration of phosphocholine (PCho) is commonly detected in 
many cell lines derived from human tumours (Bhakoo et al, 1996). It has been 
suggested that an alteration of the phospholipid metabolism resulting in 
increased intracellular PCho levels leads to cell transformation to tumour 
(Cuadrado et al, 1993; Lacal et al, 1987). Studies using nuclear magnetic 
resonance (NMR), which are capable of detecting abnormal phospholipid 
metabolism, have demonstrated that the levels of PCho are much higher in 
many tumours in comparison to corresponding normal tissues (Aboagye and 
Bhujwalla, 1999; Eliyahu et al., 2007).  All these studies have pointed at the 
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PCho as a malignancy marker useful for the diagnosis and monitoring of the 
cancer progress (Beloueche-Babari et al, 2010). Furthermore using PET 
technology, choline metabolism has been used for cancer diagnosis and more 
importantly for monitoring response to drug therapy in patients with breast 
cancer ( Kenny et al, 2010).  
 
Enhanced choline transport and ChoK mediated phosphorylation are the 
major mechanism of PCho accumulation in tumour cells (Glunde et al, 2004). 
Previous studies have also found that the ChoK, especially its isoform 
Choline kinase alpha (CHKA), is contitutively activated in many human 
tumour cells (Aoyama et al, 2004). In other studies, CHKA is found to act as 
prognostic factor in cancers such as lung and bladder  (Ramirez de Molina et 
al, 2007; Hernando et al, 2009). 
 
Though non-metastasizing, desmoid tumours are locally invasive. Choline 
metabolism in desmoid tumour has not been investigated before.  
 
9.3 Hypothesis and aim  
 
The aim of this study was to investigate CHKA as a marker of choline 
metabolism in desmoid tumour using the in-vitro model. Detection of over 
expressed CHKA would then allow for further studies of the choline 
metabolism pathway in these tumours. This may ultimately offer the 
opportunity to explore the potential role of choline based PET scan in the 
early identification of aggressive desmoids. 
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9.4 Materials and methods 
 
9.4.1 Samples 
 
One confirmed desmoid cell line (D3), one FAP fibroblast cell line (C1) and 
one non -FAP fibroblast cell line (C2) were used for this study. 
 
9.4.2 Methods  
 
Cell culture (section 7.5.1), RNA extraction (section 7.5.4) and cDNA synthesis 
(section 7.5.5) was performed as described in the chapter 7. CHKA expression 
was studied by qPCR using Platinum@SYBR@Green qPCR Supermix 
(Invitrogen, UK) in ABI prism 7900 HT Sequence Detector System (Applied 
Biosystems). Primer sequences (section 7.4) and thermal cycles used for qPCR 
(section 7.5.7) are detailed in chapter 7. qPCR reactions were performed in 
triplicates and analysed using SDS software V 2.4 (Applied Biosystems). To 
determine the mRNA fold change of CHKA the ∆∆Ct quantitation method 
was used taking PPIA as house keeping gene. 
 
9.5 Results 
 
The mRNA expression analysis by qPCR did not detect significant up 
regulation of CHKA in the desmoid tumour cell line. The result of this 
experiment is summarised in fig 9.2.  
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Fig 9.2 - qPCR for CHKA in desmoid tumour cell line (D3) and FAP fibroblast cell line (C1) in 
relation to non-FAP fibroblast cell line (C2) normalised to endogenous control PPIA; means 
and SD are shown 
 
9.6 Conclusion 
 
While increasing evidence in the literature has pointed towards the role of 
CHKA in cell proliferation, transformation and carcinogenesis and supported 
the use of this enzyme as a novel target for treatment of various tumours, this 
did not seem to be the case in the desmoid tumour cell line in the current 
study.  
 
However only one desmoid cell line was used and there were no cell lines to 
compare between the aggressive and relatively benign desmoid tumours. The 
cell line used in this study was established from an AWD with relatively 
benign course. It may be possible that the CHKA is selectively more active in 
the aggressive form of the tumour. Further studies are needed using the cell 
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lines established from quiescent and aggressive desmoid tumours to compare 
and confirm whether or not choline metabolism is activated in these tumours.  
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Chapter 10 
 
 
In vitro studies of Wnt signalling pathways in desmoid 
tumour in FAP  
 
10.1 Background 
 
Wnt proteins are secreted morphogens that are required for basic 
developmental processes such as cell fate specification, cell proliferation and 
the control of asymmetric cell division. Based on their biological activity, the 
Wnt proteins are primarily divided into two classes. The canonical Wnts 
(Wnt1/Wg class) which include Wnts 1, 3, 3a and 8 and the non-canonical 
Wnts (Wnt5a class) which include Wnts 4, 5a, 5b and 11. Based on these 
proteins, two Wnt signalling pathways are described, canonical Wnt 
signalling and non-canonical Wnt signalling (Uysal-Onganer and Kypta, 
2011). 
 
10.2 Canonical Wnt signalling pathway 
 
In the canonical Wnt pathway, the major effect of Wnt ligand binding to the 
frizzled/LRP5/6 receptor complex is the stabilisation of cytoplasmic β-
catenin through inhibition of the β-catenin degradation complex formed by 
APC, GSK3 and Axin proteins. β-catenin is then free to enter the nucleus and 
activate Wnt-regulated genes through its interaction with TCF family 
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transcription factors. In the normal pathway, APC and Axin prevent β-catenin 
from travelling to the nucleus by engaging it in the destruction complex. 
However, an APC deficiency (as in FAP) prevents β-catenin degradation and 
leads to excessive cell proliferation and formation of tumours.  
 
 
 
Fig 10.1 - Canonical Wnt signalling pathway (adapted from Sugimura et al, Birth Defect 
Research (Part C) 90: 243-256 (2010)) 
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10.3 Non-canonical Wnt signalling pathway 
 
Binding of Wnt ligands to the frizzled and other receptors (such as ROR2) 
initiates non-canonical Wnt signalling pathways. Signalling is mediated by 
dishevelled proteins, which can activate the JNK pathway to regulate cell 
motility. Intracellular calcium is another important mediator of non-canonical 
Wnt signalling. An increase of calcium ions activates the CaMKII-TAK1-NLK, 
PKC-Cdc42, and calcineurin-NFAT pathways that regulate polarity of cells. 
Non-canonical Wnt signalling regulates early embryo development, 
neurogenesis, skin morphogenesis and bone formation; the mechanism is 
through regulation of cellular motility and polarity. Also, non-canonical Wnt 
signalling antagonises canonical Wnt signalling (Sugimara et al, 2010). 
 
 
Figure 10.2 - Non-canonical Wnt signalling pathway (adapted from Sugimura et al, Birth 
Defect Research (Part C) 90: 243-256 (2010)) 
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10.4 Evidence of Wnt signal activation in desmoid tumours 
 
The majority of data regarding Wnt signal activation in desmoid tumours 
come from studies of sporadic desmoid tumours and primarily relate to the 
canonical Wnt signalling pathway. Tejpar et al studied forty-two surgically 
resected sporadic desmoid tumours and reported increased β-catenin protein 
expression in all the lesions. They found that 22 of 42 tumours contained a β-
catenin mutation and 9 contained an APC mutation, both resulting in the 
stabilisation of β-catenin protein in the cells (Tejpar et al, 1999). A further 
study using 10 sporadic desmoid tumours identified universal expression of 
TCF-3 in these tumours, in contrast to colon cancer, which expresses TCF-4 
and TCF-1. This study has suggested that the interaction unique to TCF-3 
could be responsible for the expression of different β-catenin mediated target 
genes in desmoid tumours. This could partially explain the difference in cell 
behaviour observed between desmoid tumours and other neoplastic process 
such as colon cancer that exhibits β-catenin stabilisation (Tejpar et al, 2001). 
Using six cases of sporadic desmoid from the extremities, Alman et al have 
reported a higher level of β-catenin protein expression in desmoid tumour 
compared to surrounding normal tissue (Alman et al, 1997).  
 
Due to the ‘double hit’ mutation in the APC gene resulting in abnormal APC, 
the β-catenin destruction complex formed by APC, Axin and GSK3 is 
inefficient in FAP-associated desmoid tumours. This results in the 
stabilisation of β-catenin, which would be predicted to lead to constitutive 
activation of canonical Wnt signal in FAP-associated desmoid tumours.  
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The non-canonical Wnt signalling pathway has not been studied in desmoid 
tumours. The available data, mainly from animal studies, suggest that the 
non-canonical Wnt signalling plays an important role during embryo 
development and the regulation of tissue development and homeostasis 
(Sigimura et al, 2010).  Wnt-11, a secreted non-canonical Wnt protein is 
primarily responsible for modulating cell growth, differentiation and 
morphogenesis during development. However, high expression of Wnt-11 
detected in gastric, prostate and renal cell carcinoma cell lines and some 
primary colorectal adenocarcinomas, has suggested a role in human cancer 
development (Kirikoshi et al, 2001). Moreover in prostate cancer, Wnt-11 was 
found to induce neuroendocrine-like differentiation of cancer cells (a more 
aggressive form of cancer), enhance cancer cell survival and promote cancer 
cell migration (Uysal-Onganer et al, 2010). 
 
10.5 Aims of the study 
 
The main aim of this study was to investigate the activation of canonical and 
non-canonical Wnt signalling pathways in FAP associated desmoid tumour. 
 
10.6 Materials and methods 
  
10.6.1 Sample 
 
A FAP associated desmoid tumour cell line (D3); FAP fibroblast cell line (C1) 
and a non-FAP fibroblast cell line (C2) were used. Formalin fixed paraffin 
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embedded sections of desmoid tumour were used for immunohistochemistry 
analysis.	   
 
10.6.2 Methods 
 
The cells were grown using standard cell culture technique. RNA extracted 
from each cell line using an established protocol was used to prepare cDNA. 
Using RT-PCR and qPCR Wnt target genes AXIN2 (canonical) and WNT11 
(non-canonical) were studied in the desmoid and control cell lines. Protein 
was extracted from the cells using standard technique (see section 7.5.8) and 
Western blot analysis was performed for β-catenin and Wnt-11 proteins. Cells 
were grown on cover slips and stained with β-catenin antibody for 
immunocytochemistry analysis.  
 
Paraffin embedded sections of the desmoid tumour from which the cell line 
was established were stained with β-catenin and Wnt-11 antibodies for 
immunohistochemistry analysis. The histology slides were reviewed with the 
pathologist experienced in desmoid tumour reporting. 
 
The details of materials, methods, primers and antibodies used in these 
experiments are listed in the chapter 7. 
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10.7 Results 
 
10.7.1  Studies of the canonical Wnt signalling pathway  
 
10.7.1.1 β-catenin immunocytochemistry 
 
Immunocytochemistry detected cytoplasmic β-catenin expression in all the 
cell lines (D3, C1 and C2). However nuclear localisation of β-catenin was only 
observed in the desmoid tumour (D3). Fig 10.3 demonstrates the result of 
immunocytochemistry analysis on these cell lines.  
 
         
A      B 
 
C 
Fig	  10.3	   -­‐	  β-catenin immunocytochemistry in 
desmoid (A), FAP fibroblast (B) and non-FAP 
fibroblast (C) cell lines. Nuclear localisation 
of β-catenin is demonstrated in the desmoid 
tumour cell line (arrow, A)	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10.7.1.2 β-catenin western blot 
 
Western blot analysis of β-catenin protein in the desmoid and control cells did 
not show any significant difference in the total protein level. Fig 9.4 depicts 
the result of western blot analysis of β-catenin protein; heat shock protein 60 
(HSP60) was used as loading control in this experiment. 
 
  
 
 
 
Fig 10.4 - Representative result of western blot analysis of β-catenin protein in desmoid 
tumour (D3), FAP fibroblast (C1) and Non-FAP fibroblast (C2) cell lines 
 
10.7.1.3 β-catenin immunohistochemistry 
 
Widespread nuclear β-catenin expression was evident in the section from the 
desmoid tumour from which the cell line was created. Fig 9.5 demonstrates 
the histology findings. 
 
	  	  	  D3   C1   C2 
β catenin 	  
HSP60	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A           B 
 
Fig 10.5 - Low (A, 10x) and high (B, 40x) resolution pictures of histology slides of desmoid 
tumour (D3) demonstrating widespread nuclear β-catenin expression 
 
10.7.1.4 AXIN2 PCR and qPCR 
 
AXIN2 as a downstream target of canonical Wnt activation was studied using 
RT-PCR and qPCR techniques. The desmoid tumour cell line demonstrated 
overexpression of AXIN2, compared to control cell lines by RT-PCR. This 
overexpression was found to be 22-fold in the desmoid in comparison to 
control cells using qPCR. Fig 10.6 and 10.7 depict the results of PCR and qPCR 
studies in these cell lines respectively. 
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Fig 10.6 – RT-PCR depicting overexpression of AXIN2 in desmoid cell line (D3). GAPDH used 
as loading control. L: DNA ladder 
 
 
 
Fig 10.7 - qPCR analysis of AXIN2. A 22-fold over expression of AXIN2 was detected in 
desmoid tumour (D3) cells; means and SD are shown 
     L            D3    C1           C2 
AXIN2 
GAPDH 
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10.7.2  Studies of non-canonical Wnt signalling pathway 
 
10.7.2.1  WNT11 PCR and qPCR 
 
WNT11 was studied using RT-PCR and qPCR techniques to investigate the 
non-canonical Wnt signalling pathway. Both RT-PCR and qPCR methods 
detected overexpression (55-fold by qPCR) of WNT11 in desmoid tumour 
cells, compared to controls. Fig 10.8 and 10.9 demonstrate the results of these 
studies.  
  
 WNT11 
   
  GAPDH 
 
Fig 10.9 - WNT11 qPCR. WNT11 expression was 55-fold higher in desmoid tumour (D3), 
means and SD are shown 
L D3 C1 C2    PC3 
Fig 10.8 - WNT11 RT-PCR. An over expression of 
WNT11 was detected in desmoid tumour (D3) cell 
line. L: DNA ladder, PC3: prostate cancer cell line, 
positive control for WNT11 	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10.7.2.2  Wnt-11 western blot 
 
No significant difference in the expression of Wnt-11 protein was 
demonstrated by western blot analysis among the cell lines. Fig 9.10 
demonstrates the result of western blot analysis. 
 
 
 Wnt-11 
 HSP 60 
 
Fig 10.10 - Representative result of Wnt-11 western blot analysis. No significant difference in 
expression of Wnt-11 protein was detected among the cell lines 
 
10.7.2.3 Wnt-11 immunohistochemistry 
 
Immunohistochemistry analysis of Wnt-11 on the desmoid tumour sections 
detected wide expression of Wnt-11. For control these slides were only 
stained using secondary antibody. Fig 9.11 depicts Wnt-11 histology results. 
 
   D   C1   C2	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A       B 
                          
C       D    
 
Fig 10.11 - Immunohistochemistry of Wnt-11 in desmoid tumour. A and B are 10x and 40x 
magnification of the desmoid tumour sections; widespread cytoplasmic and nuclear 
expression of Wnt-11 (brown stain) is demonstrated. C and D are the 10x and 40x 
magnification of control slides stained with secondary antibody only 
           
10.8 Discussion 
 
In vitro studies using a desmoid tumour cell line detected nuclear localisation 
of β-catenin and overexpression of the canonical Wnt target gene AXIN2. In 
this study, the β-catenin protein level was not found to be significantly 
different among the desmoid and control fibroblast cell lines. However the 
nuclear localisation of β-catenin in desmoid tumour was evident by 
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immunohistochemistry, which detected widespread nuclear β-catenin 
localisation in the desmoid tumour section from which the primary cell line 
was established.  
 
The finding of nuclear localisation but not overtly increased β-catenin in the 
desmoid tumour cells in this study suggests that while the level of β-catenin 
protein is same in all the cell lines, the inefficient degradation complex in 
desmoid due to APC mutation results in β-catenin stabilisation resulting in its 
translocation to nucleus to interact with TCF factor. In addition, any increase 
in cytoplasmic and nucler β-catenin in the desmoids may be masked by the 
pool of cadherin-associated β-catenin in the membrane. 
 
AXIN2 is a negative regulator of the Wnt/β-catenin pathway. J Eek-Hoon et 
al reported that activation of the Wnt/β-catenin/TCF signalling pathway 
induces the transcription of AXIN2, using a mouse model and mouse cell 
lines (Eek-hoon et al, 2002). In a further study using 30 human cell lines 
derived from different origins, Yan et al detected AXIN2 overexpression only 
in human colon cancer cell lines that were known to have activating 
mutations in the Wnt/β-catenin pathway (Yan et al, 2001). The findings from 
these studies suggest that the overexpression of AXIN2 provides firm 
evidence of the Wnt/β-catenin pathway activation. Hence the findings of 
AXIN2 overexpression combined with the nuclear localisation of β-catenin in 
the desmoid tumour cell line in this study confirms that the Wnt/β-catenin 
pathway is activated in the desmoid tumour.  
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WNT11, the non-canonical Wnt, was overexpressed in desmoid tumour cells 
in these experiments. The immunohistochemistry also detected expression of 
the Wnt-11 in the desmoid sections from which the cell line was established. 
However at the protein level no significant difference in the expression was 
detected amongst desmoid and control cell lines. Wnt-11 is a secreted protein 
so its level in cell extracts may not reflect total expression levels. The nuclear 
staining for Wnt-11 is unexpected, but not unprecedented. Nuclear Wnt-11 
has been observed in chronic myeloid leukemia. 
 
 Wnt-11 is reported to promote cellular motility and enhance cellular survival. 
The overexpression of Wnt-11 in desmoid tumour cells may be the 
contributing factor for selection of desmoid tumour cells and their survival in 
the culture. Further studies are required to confirm the interesting finding of 
the current study.  
 
Antibodies to Wnt-11 are still being purified and available antibodies are not 
100% specific. This could be one of the reasons for Wnt-11 protein result in 
this experiment. The unstable nature of Wnt-11 protein could be another 
contributing factor. Further studies in future with more purified antibody to 
Wnt-11 will help clarify this further. 
 
10.9 Summary 
 
In summary, the in vitro studies of Wnt signalling pathways confirmed that 
Wnt/β-catenin (canonical Wnt signal pathway) pathway is activated in the 
desmoid tumour. Wnt-11, the non-canonical Wnt is also overexpressed in 
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desmoid tumour. Further work using more desmoid cell lines is needed to 
validate and explore these findings in greater detail. Validation of these 
findings will provide a unique opportunity to explore the role of Wnt 
inhibitors in desmoid tumour.  This may ultimately lead to identification and 
development of novel therapy to treat this intriguing condition. 
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PART FIVE – CONCLUSION 
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Chapter Eleven 
 
Conclusion  
 
Desmoids are a major cause of morbidity and mortality in patients with FAP. 
The variable nature of the desmoid tumours, and the lack of reliable 
molecular, pathological or clinical markers of aggressive disease, makes  early 
identification of aggressive desmoid difficult. Surgical excision incurs high 
recurrence, and high morbidity in case of IAD. Furthermore, there is lack of 
high quality evidence on the efficacy of available non-surgical/medical 
treatment. Desmoids therefore remain as an outstanding challenge in the 
management of FAP patients.  
 
The available literature usually combines sporadic and FAP associated 
desmoids, which are biologically distinct entities. The studies described in 
this thesis focus exclusively on FAP-associated desmoids and attempt to 
further characterise these tumours.  
 
A potential role of modern functional and metabolic imaging in identifying 
the aggressive minorities of desmoid tumours has been explored and in-vitro 
studies have investigated the molecular pathways in this enigmatic tumour.  
	   178	  
11.1 Imaging studies  
 
The radiology studies described in Part Two of this thesis investigated the 
role of modern imaging modalities in the evaluation of desmoid tumours. The 
first study in Chapter Three of this thesis demonstrated that modern day MRI 
is at least equivalent and probably superior to cross-sectional CT for the 
radiological evaluation of desmoids in patients with FAP. MRI also has the 
advantage of lack of radiation exposure to young patients with FAP, who are 
frequently affected by desmoids.  
 
Chapter Four explored the use of diffusion weighted imaging (DTI) in 
desmoid tumours. This is the first reported study in FAP desmoids and 
confirms that DTI is feasible in these tumours. Desmoid tumours show 
anisotropic diffusion, which is less directional than in muscle. This forms a 
foundation to explore the role of this imaging modality in desmoid tumour in 
future using a bigger study population. 
 
Chapter Five of this thesis has investigated the potential role of functional (18F 
FDG PET CT) and vascular imaging (DCE-MRI) in identifying growing 
desmoid tumours. This study found that desmoid tumours were generally 
hypovascular and, contrary to the other few studies showing high glucose 
avidity, were poorly glucose avid. While the study was not conclusive for 
finding any definite parameter predictive of aggressive tumour behaviour, it 
demonstrated a spectrum of findings in FAP-associated desmoid tumours 
that will be an invaluable asset to refer to for the future studies using larger 
sample size.  
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11.2 Clinical study 
  
The clinical study described in Part Three of the thesis has reviewed 
management of IAD presenting with air-fluid level in cross sectional imaging. 
The study showed that some patients with IAD with air-fluid level could be 
treated with a conservative approach of antibiotics with or without a 
percutaneous drain; the others ultimately required complex surgery. Based on 
this study a management algorithm has been proposed to treat such patients. 
 
11.3 Laboratory studies 
  
Using the primary cell lines established from desmoid tumours, the first 
laboratory based study (Chapter 8) was performed to identify APC mutations 
in the cells. This study successfully identified a ‘second hit’ somatic mutation 
in the APC gene in one of the three cell lines investigated and confirmed the 
establishment of a true desmoid tumour cell line. 
 
The confirmed desmoid tumour cell line was then used along with controls to 
study the choline metabolism pathway (Chapter 9) and the Wnt signalling 
pathways (Chapter 10). While the study described in this thesis failed to 
demonstrate up-regulation of choline metabolism in desmoid tumour cells, 
the activation of canonical Wnt signalling pathway was established. 
Interestingly Wnt-11, a non-canonical Wnt, was found up regulated in 
desmoid tumour cells. Further studies are needed to confirm whether 
expression of Wnt-11 may be responsible for the selection and survival of true 
desmoid tumour cells in culture.  
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Chapter Twelve 
 
 
 
Future work 
 
12.1 Prognostication of desmoid with modern functional imaging 
 
The DTI, DCE-MRI and 18F FDG PET CT imaging studies described in this 
thesis have confirmed the feasibility of such studies and shown a spectrum of 
findings in FAP associated desmoid tumours. However only a small number 
of patients were studied and the included subjects were already on available 
treatment before the commencement of the study, which might have 
influenced some of the study findings. Moreover only one patient had a really 
aggressive desmoid tumour who unfortunately died due to desmoid before 
the follow up scan could be performed.  
 
A study involving larger number of patients, with a practice of imaging the 
desmoid with functional and metabolic imaging first and then starting the 
medical treatment, may help to clarify the role and the value of these imaging 
modalities in the early assessment of aggressive phenotype of desmoid 
tumours, and also the assessment of success or failure of a particular modality 
of treatment.  
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12.2 Validation of Wnt signal activation in desmoid tumours 
 
The laboratory-based studies described within this dissertation have 
established the activation of the Wnt signalling pathway in desmoid tumour. 
The demonstration that the β-catenin protein is stabilised in these tumours 
suggests blockade of the Wnt-APC-β catenin pathway as potential treatment. 
However this interesting finding has been described in this thesis using the 
in-vitro model of single cell line. There is need for establishment of more 
desmoid tumour cell lines and reproducing the result of these experiments to 
validate the findings of this initial work. As more is learned about the role of 
mediators in the Wnt signaling cascade and the downstream genes that 
regulate proliferation, a novel therapeutic approach may be devised based on 
blockade of this signalling pathway. Adjuvant treatments based on 
manipulation of cellular growth control may improve the outcome for 
individuals with this disorder and perhaps a treatment based on modulation 
of the function of Wnts or manipulation of downstream mediator could be 
devised. Establishment of more desmoid tumour cell lines and further work 
on Wnt signalling pathway is currently underway in our institution. 
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APPENDICES 
 
A1 Collaborations and assistance 
 
A1.1 Imaging studies 
 
The 64-MDCT was performed at the Intestinal Imaging Centre, St Mark’s 
Hospital, under supervision of Dr Arun Gupta and Dr David Burling. The 
1.5T MRI, DTI, DCE-MRI and 18F FDG PET CT were performed at Paul 
Strickland Scanner Centre, Mount Vernon Hospital, Northwood under 
supervision of Professor Vicky Goh and Dr Luke Sonada. Ethical approval for 
imaging studies was obtained by Mr Salman Rana, Clinical Research Fellow, 
Polyposis Registry, St Mark’s Hospital, Harrow. Patients were recruited for 
initial study by Mr Ashish Sinha, Clinical Reseach Fellow, St Mark’s Hospital. 
I was involved in organising follow up scans, data gathering and analysis as 
explained in individual studies below. 
 
Chapter 3 - A prospective comparision of 64-slice multidetector computer 
tomography and 1.5- Telsa magnetic resonance imaging in the assessment 
of desmoid tumours in familial adenomatous polyposis 
 
The 64-MDCT and MRI images were interpreted by Professor Vicky Goh, Dr 
Arun Gupta and Dr David Burling. I collected the data and performed 
statistical analysis for this study.  
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Chapter 4 - Diffusion tensor imaging (DTI) in the assessment of desmoid 
tumours in familial adenomatous polyposis 
 
I gathered the quantitative data from the DTI images using commercial 
tensor software (Neuro3D, Siemens Healthcare) under direct supervision of 
Professor Vicky Goh. I also performed the data analysis and the statistical 
tests for this study.  
  
Chapter 5 - Role of Dynamic Contrast Enhanced Magnetic Resonance 
Imaging (DCE-MRI) and Fluorine-18 Flurodeoxyglucose Positron Emission 
Tomography (18F-FDG PET) in predicting behaviour of desmoid tumours 
in familial adenomatous polyposis 
 
Under direct supervision of Prof Vicky Goh, I generated the quantitative 
DCE-MRI data after drawing ROI around individual tumour on a 
workstation using proprietary software (MRIW, Royal Marsden Hospital). Dr 
Luke Sonada helped to generate the FDG PET data for the study. I also 
analysed the data and performed all the statistical tests for the study. 
  
A1.2 Clinical study 
 
Chapter 6 - A clinical review of familial adenomatous polyposis associated 
desmoid tumours presenting with air fluid level 
 
I identified the study patients from the Polyposis Registry database and 
reviewed all the notes. I collected the data for this study, analysed it and 
developed the treatment algorithm described in the study.  
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A1.3 Laboratory studies 
 
Chapter 8 - APC mutation analysis in FAP desmoids and fibroblast cell 
lines 
 
I performed cell culture and submitted the pellets of desmoid and control cell 
lines for the APC mutation analysis. The full sequence APC mutation analysis 
was performed at the Kennedy-Galton Centre, Northwick Park and St Mark’s 
Hospital, under supervision of Dr Stewart Payne using automated DNA 
sequencer.  
 
Chapter 9 - Study of choline metabolism in desmoid tumour in FAP  
 
 
This work was done, in collaboration with Professor Eric Aboyage and Dr 
Rohini Sharma, at Comprehensive Cancer Imaging Centre, Cyclotron 
Building, Hammersmith Hospital. I designed and performed all the 
laboratory experiments (TC, RNA extraction, cDNA synthesis, qPCR for 
CHKA and data analysis) under supervision of Dr Rohini Sharma. 
 
 
Chapter 10 - In vitro studies of Wnt signalling pathways in desmoid 
tumour in FAP  
 
This work was performed at the Institute of Reproductive and Developmental 
Biology (IRDB, Hammersmith Hospital, Imperial College London) under 
supervision of Dr Robert Kypta. I designed and performed all the laboratory 
experiments for this study, except the qPCR for AXIN2 and WNT11. Dr Nora 
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Bengoa (Cell Biology and Stem Cells Unit, CIC bioGUNE, Bizkaia, Spain) 
performed the qPCR for AXIN2 and WNT11, under supervision of Dr Robert 
Kypta (I supplied the cDNA required for the experiment). Dr Morgen 
Moorghen, St Mark’s Hospital, reviewed the immunohistology slides of this 
study. 
 
 
A2 Regulatory approvals 
 
Ethical approval from the Harrow Research and Ethics Committee along with 
research and development approval from the North West London Hospitals 
NHS Trust was obtained for the studies described in this thesis. Listed below 
are the details of these approvals. 
 
 
 
Title 
 
 
Harrow REC 
Number 
 
 
NWLH NHS 
R&D Number 
 
 
Date of Approval 
 
 
Carcinogenesis of desmoid 
disease in familial 
adenomatous polyposis 
 
 
08/H0719/75 
 
 
RD8/080 
 
 
25th February 2009 
 
 
Immunohistochemical 
analysis and treatment of 
familial adenomatous 
polyposis related desmoids 
 
 
09/H0709/13 
 
 
RD9/011 
 
 
21st April 2009 
 
 
The role of imaging in the 
assessment of desmoid 
tumour growth: a 
comparison of CT, MRI and 
PET scanning 
 
 
07/H0719/100 
 
 
RD7/090 
 
 
5th March 2008 
 
	   200	  
A3 Publications in peer reviewed journals  
 
The following paper publications in peer-reviewed journals have resulted 
from the studies described in this thesis. 
 
1. Chapter three: Imaging assessment of desmoid tumours in familial 
adenomatous polyposis: is state-of-the-art 1.5 T MRI better than 64-MDCT? 
Sinha A, Hansmann A, Bhandari S, Gupta A, Burling D, Rana S, Phillips RK, 
Clark SK, Goh V. Br J Radiol. 2012 Jul;85(1015):e254-61.  
 
2. Chapter four: Diffusion tensor imaging (DTI) of desmoid tumours in 
familial adenomatous polyposis: initial experience. Bhandari S, Sinha A, Tam 
E, Stirling JJ, Simcock I, Clark S, Goh V. Eur J Radiol. 2012 Nov;81(11):3646-51.  
 
3. Chapter five: Can combined 18F-FDG-PET and dynamic contrast-enhanced 
MRI predict behavior of desmoid tumors in patients with familial 
adenomatous polyposis? Bhandari S, Taylor NJ, Sinha A, Sonoda L, Sanghera 
B, Wong WL, Goh V, Clark SK. Dis Colon Rectum. 2012 Oct;55(10):1032-7.  
 
4. Chapter six: Familial adenomatous polyposis-related desmoids presenting 
with air-fluid level: a clinical review and management algorithm. Bhandari S, 
Ranchod P, Sinha A, Gupta A, Clark SK, Phillips RK. Dis Colon Rectum. 2012 
Jul;55(7):810-4.  
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A4 Presentations of the research work 
 
The following presentations resulted from the work carried out in this 
dissertation.  
 
A4.1 Oral presentations 
 
1. In-vitro studies of the Wnt signalling pathways in FAP desmoid. Society of 
Academic and Research Surgery (SARS), 9-10 Jan 2013. 
 
2. Is modern day MRI better than CT for assessment of desmoid tumours in 
familial adenomatous polyposis? The Association of Surgeons in Training 
(ASiT), 23-25 March 2012; 2011 Colorectal Tripartite Meeting, Cairns, 
Australia, 3-7 July, 2011 
 
A4.2 Poster presentations 
 
1) In-vitro studies of the Wnt signalling pathways in desmoid tumour in 
familial Adenomatous polyposis. European Society of Coloproctology(ESCP), 
Vienna, 26-28 September 2012. 
 
2) Can combined Fluorine- 18 Fluorodeoxyglucose Positron Emission 
Tomography (18 F – FDG PET) and Dynamic Contrast Enhanced Magnetic 
Resonance Imaging (DCE-MRI) predict behaviour of desmoids tumours in 
familial adenomatous polyposis (FAP) patients? Society of Academic and 
Research Surgery (SARS), Nottingham, 4-5 Jan 2012. 
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3) Diffusion Tensor Imaging (DTI) of desmoids tumours in familial 
adenomatous polyposis : initial experience. Society of Academic and Research 
Surgery (SARS), Nottingham, 4-5 Jan 2012. 
 
4) Dynamic contrast enhanced magnetic resonance imaging of desmoid 
tumours in familial adenomatous polyposis. 4th Biennial Meeting: 
International Society for Gastrointestinal Hereditary Tumours (InSiGHT), San 
Antonio, Texas, March 31- April 2, 2011. 
 
 
 
 
 
 
 
